live-centre-files1000true1/BSACMaintenanceAugust2013.pdf2016-11-27T12:53:38.000Z"4a37465b3cffa38365f393beed5c32c1"78428STANDARD1/BSACMaintenanceDec2013.pdf2016-11-27T12:53:39.000Z"6d151b06b2ddac424ceba15bc2acae9b"79235STANDARD1/GuidanceforPrescribingandMonitoringGentamicin.docx2016-11-27T12:53:39.000Z"30d7127e44af87a99636032e8397ba44"51094STANDARD1/GuidanceforPrescribingandMonitoringGentamicin.pdf2016-11-27T12:53:39.000Z"7e06480277b2a10079e6948491d5ee2a"161683STANDARD1/GuidanceforPrescribingandMonitoringTeicoplanin.docx2016-11-27T12:53:39.000Z"d5fe3deac09545cb8751d48b304dd172"44263STANDARD1/GuidanceforPrescribingandMonitoringTeicoplanin.pdf2016-11-27T12:53:39.000Z"ff4c728f95d107333584209b479aacfd"137023STANDARD1/GuidanceforPrescribingandMonitoringVancomycin.docx2016-11-27T12:53:40.000Z"49762ec971ca18a9fa4fcc2cf1a303ea"48176STANDARD1/carlogoPNG1667.png2016-11-27T12:53:39.000Z"b82eac4470384cb2b409b0bdab97646d"65198STANDARD1/image2.jpg2016-11-27T12:53:40.000Z"57f9395838282b6c5e6008ff2e8d084f"6524STANDARD103/appdraft2.png2019-05-21T15:15:14.000Z"2163611e03da7545df41eb88088a0f22"54653STANDARD103/flowdiagramfoapp.docx2019-05-21T15:10:18.000Z"96dc4f434c3f913bb583c6931fc70e5b"36133STANDARD103/flowdiagramforapp.png2019-04-24T15:52:42.000Z"e2907db4ee5d935c6c05ed80c896adfa"135009STANDARD103/flowdiagramforappuse2.png2019-04-24T15:47:04.000Z"8cd76ae1c504084314f3a86449847f1d"88606STANDARD103/sepsis3hourreviewmay2019.png2019-05-21T15:29:24.000Z"706f2b70c053b245d8b62772bf8803c1"40823STANDARD103/sepsisinitialtreatmentmay2019.png2019-05-21T15:24:05.000Z"dec354a488a2248e024965b4914ca32a"68172STANDARD107/CDI.png2016-11-27T12:54:13.000Z"4080c1f8728b9c268b537d203d92e0bc"65495STANDARD107/ECBU.jpg2016-11-27T12:54:14.000Z"06cc769915caaf2a1cfe5bd9d49bbcfc"207083STANDARD107/LCR.jpg2016-11-27T12:54:15.000Z"df75cce4d2b14949d85c3a5abc2f29a9"158198STANDARD107/ORL.png2016-11-27T12:54:15.000Z"924c0112653fb828a03bf9e10f941925"80194STANDARD107/Sanstitre.jpg2016-11-27T12:54:19.000Z"fa80f5a51b63c2ca873547fc38b090cc"95286STANDARD107/Staf.jpg2016-11-27T12:54:19.000Z"41e248b81b18a38ab8e648b032bf71a7"58787STANDARD107/TPE.png2016-11-27T12:54:20.000Z"df14c7500333f2cf47ec85d3a94ac674"37882STANDARD107/antibiolor.png2016-11-27T12:54:12.000Z"f0308506adfc60e4038458835d08e6ce"18904STANDARD107/bariatr.png2016-11-27T12:54:12.000Z"62d7b491f77cfc5efaa5d5e86e1592f8"93678STANDARD107/card.png2016-11-27T12:54:13.000Z"8b538269a850980e554e7c6a0565c4f0"77358STANDARD107/cytomegalo.jpg2016-11-27T12:54:13.000Z"8d5c55d39daf06776290b46be05ba3a9"83795STANDARD107/desescaladepneumnosoc.jpg2016-11-27T12:54:13.000Z"1f7ecffeddc9a335bdef52bb42bb46bd"55696STANDARD107/dig.png2016-11-27T12:54:14.000Z"b8722e60384c1d72528796b75d12da04"122304STANDARD107/febrileneutropeniabasrisque.jpg2016-11-27T12:54:14.000Z"0c2de0fc6415cfc92a4bbb4801de5240"88218STANDARD107/febrileneutropeniahautrisque.jpg2016-11-27T12:54:14.000Z"124733c678308e2c733982a8e3a01028"174983STANDARD107/gyneco.png2016-11-27T12:54:14.000Z"153c3231054a477f7c280a6acf121c93"81148STANDARD107/interactions.jpg2016-11-27T12:54:14.000Z"65f5d8c7639b0a17aac20448a6b402d8"42542STANDARD107/neuro.png2016-11-27T12:54:15.000Z"f3aafc55a7ca875c94b75f96cd232a8d"88472STANDARD107/new.doc2016-11-27T12:54:15.000Z"da377b6f59516757d3d24d603438a099"35328STANDARD107/ocul.png2016-11-27T12:54:15.000Z"47c077820e19013b1bed2a86c0c142c6"41408STANDARD107/ortop1.png2016-11-27T12:54:15.000Z"e3706932db9d65407eb34b06785e373e"79693STANDARD107/ortop2.png2016-11-27T12:54:15.000Z"fb84798af35b53f76aad5b5bff4846ba"101010STANDARD107/ortop3.png2016-11-27T12:54:16.000Z"9d882bfc5c232d79b890af66212007cd"113051STANDARD107/parvo.jpg2016-11-27T12:54:16.000Z"2dbeaf884b51c5a71cc66b033a10bc09"70720STANDARD107/perf1.png2016-11-27T12:54:16.000Z"45319c2605f50b84930c6302238e65f9"117067STANDARD107/perf2.png2016-11-27T12:54:16.000Z"71657dcefb8d670310e6fd1da758fa2d"116027STANDARD107/perf3.png2016-11-27T12:54:17.000Z"1d2f69723525907448f9d8459002a027"142054STANDARD107/perf4.png2016-11-27T12:54:17.000Z"e7211f46a2dbc5956555500386879b7a"133206STANDARD107/perf5.png2016-11-27T12:54:17.000Z"d92c009f202523e0150a4f8ad1fbac57"140605STANDARD107/perf6.png2016-11-27T12:54:17.000Z"3194a70f4cbedabfe743da2937607be1"142156STANDARD107/perf7.png2016-11-27T12:54:17.000Z"a0630fd10d0228149b33ca9ccdf63751"147009STANDARD107/perf8.png2016-11-27T12:54:18.000Z"4d28e4581d984cd65d12a61b331a1f32"132844STANDARD107/perf9.png2016-11-27T12:54:18.000Z"77e3355276652be440f71e0e3e6e85f9"37798STANDARD107/plast.png2016-11-27T12:54:18.000Z"ed156b04bfc6996cb6a1f43c0ffc7a4c"47122STANDARD107/prelevresp.jpg2016-11-27T12:54:18.000Z"1a640e26ec32502ded6a9e55dc548490"190604STANDARD107/radint.png2016-11-27T12:54:18.000Z"31f08a250b08f40b4e0f4efedeb88999"98644STANDARD107/rubeole.jpg2016-11-27T12:54:19.000Z"ec68121b5aa588854517dbf38a529339"68832STANDARD107/staf2.jpg2016-11-27T12:54:19.000Z"ea7bf98bc1f8a7f9af878bd5adf34673"150699STANDARD107/strepto.jpg2016-11-27T12:54:19.000Z"d1426caa3972258463e83bf19e990bcd"79159STANDARD107/tetanus.png2016-11-27T12:54:19.000Z"24b6a2d5a7c3de5abb1c21755adcea09"34804STANDARD107/tetanus2.png2016-11-27T12:54:19.000Z"dd4f83498750bf0557b28f89d995fdb2"33417STANDARD107/torac.png2016-11-27T12:54:20.000Z"b0dc0707debb56f0fe08b7f6c0699412"69658STANDARD107/toxo.png2016-11-27T12:54:20.000Z"191ce406d808fb862d56082f0a7c8a46"90636STANDARD107/urol.png2016-11-27T12:54:20.000Z"2ca14998941b2f622592f5ff5064dcd6"115017STANDARD107/vasc.png2016-11-27T12:54:20.000Z"0ead74f97c4163178d6006fb0a345544"86463STANDARD109/285FeverPathwayClinicalAssessmentManagementToolforChildYoungerthan5Years.pdf2016-11-27T12:54:32.000Z"9374587300d8273ca4808dd068b3886c"1221218STANDARD109/287GastroenteritisPathway.pdf2016-11-27T12:54:33.000Z"719ad26ce485326ade24327320d2b247"1220822STANDARD109/385CranialUltrasoundScanCrUSSNeonates.pdf2016-11-27T12:54:38.000Z"7610a725e15b0360c4d684157d2ff93f"645181STANDARD109/387FalteringGrowthRecognitionandInvestigation.pdf2016-11-27T12:54:39.000Z"6a1b332d3e341244c22ad160f379ba69"624971STANDARD109/692Type1DiabetesMellitusinChildrenT1DM.pdf2016-11-27T12:54:51.000Z"9775b341213a05190431d6108d5846c0"351406STANDARD109/769MeningococcalDiseaseManagementPaediatrics.pdf2016-11-27T12:54:54.000Z"677605e5b7ceff0f50dea2abd2fe408e"201044STANDARD109/AmphotericinpharmacySOPguideline193.pdf2016-11-27T12:54:58.000Z"a8b85e1e1a0a96df89412790a6be5cb4"41083STANDARD109/Guideline1.pdf2016-11-27T12:55:02.000Z"2762d496d6b9095127ea4b93e19daf05"101497STANDARD109/Guideline110FM.pdf2016-11-27T12:55:03.000Z"f57426cb0ddec3b26a5a428b47f91dab"138491STANDARD109/Guideline114FM.pdf2016-11-27T12:55:04.000Z"5c7af4bf9915c346d47d260ddda9f768"205110STANDARD109/Guideline127.pdf2016-11-27T12:55:06.000Z"9a85ff5ae5a76d9eb956399637f00afa"92095STANDARD109/Guideline144.pdf2016-11-27T12:55:09.000Z"1df902cd47606618f5326c9a51cbc194"528821STANDARD109/Guideline145.pdf2016-11-27T12:55:09.000Z"d103c464cfa5f8c2671d6f073d02d84c"173581STANDARD109/Guideline14A.pdf2016-11-27T12:55:11.000Z"0ea555468056f38a44f085674dd73822"136052STANDARD109/Guideline15.pdf2016-11-27T12:55:12.000Z"55e2d220b447ead35f6fe588ad5a5f7e"179303STANDARD109/Guideline151FM.pdf2016-11-27T12:55:12.000Z"02832a3456a0e0fa532db369ef5c85d1"201746STANDARD109/Guideline165.pdf2016-11-27T12:55:14.000Z"818c0ba561bbe7dce7cb07f2f8ab7040"118794STANDARD109/Guideline169.pdf2016-11-27T12:55:14.000Z"293daaeb11e8667672970b871692f648"44065STANDARD109/Guideline171.pdf2016-11-27T12:55:14.000Z"442a9f32e7c03e8c916d842c3f8043d5"28423STANDARD109/Guideline174.pdf2016-11-27T12:55:14.000Z"e5b2ac9d5b7789815d06d23992e5711f"20661STANDARD109/Guideline195.pdf2016-11-27T12:55:17.000Z"c66b15eb4df2aaca9c6f66f1fef0b85a"26019STANDARD109/Guideline199.pdf2016-11-27T12:55:18.000Z"c1ebf0a54d8c51c51885572b2df81606"186486STANDARD109/Guideline2.pdf2016-11-27T12:55:18.000Z"ec65695ea4f25a41c51d25cba61868f9"30509STANDARD109/Guideline200.pdf2016-11-27T12:55:19.000Z"5eefdc24901f05bafb6eacec8edbde7a"1812466STANDARD109/Guideline201.pdf2016-11-27T12:55:20.000Z"611fa5e0ab683b0382984bf4fd9307bb"32046STANDARD109/Guideline205.pdf2016-11-27T12:55:21.000Z"1b0ce450c2d2e18f9b99ee3b83a533fc"55668STANDARD109/Guideline208.pdf2016-11-27T12:55:21.000Z"87272402f467d5df471f721e6e21ce7d"104420STANDARD109/Guideline210.pdf2016-11-27T12:55:22.000Z"b9b39e544d698f66d5d761445463303f"161142STANDARD109/Guideline221FM.pdf2016-11-27T12:55:25.000Z"97cf5254e9e20d72feff34f08da0bee6"209936STANDARD109/Guideline233.pdf2016-11-27T12:55:27.000Z"0fa73ddc6c40bc773ba1bf08e1745ba5"45711STANDARD109/Guideline235.pdf2016-11-27T12:55:27.000Z"2397b50642f44e430572a4c2ddd08226"28288STANDARD109/Guideline259.pdf2016-11-27T12:55:31.000Z"6dd8b188521436042ccd5d4d1717a8c9"287110STANDARD109/Guideline275FM.pdf2016-11-27T12:55:33.000Z"8a4b5fc2e55d1aa21f2bd0c244ae67a8"160331STANDARD109/Guideline280.pdf2016-11-27T12:55:35.000Z"8de20d14061b717ce995c8f870bad2ef"279426STANDARD109/Guideline293.pdf2016-11-27T12:55:37.000Z"1f82a76c8e0d543f6de68d922c529ab9"82182STANDARD109/Guideline3.pdf2016-11-27T12:55:37.000Z"447e59670767b1b0ec86d0b6f1eaabf0"31771STANDARD109/Guideline304.pdf2016-11-27T12:55:39.000Z"cfd7ad49ff355f0383f593872fa1f179"165706STANDARD109/Guideline308.pdf2016-11-27T12:55:39.000Z"13816cba82bd64dd90fabe575315a9f1"27035STANDARD109/Guideline316.pdf2016-11-27T12:55:41.000Z"7dfad35ed311a6b86a718242817d7455"37924STANDARD109/Guideline318.pdf2016-11-27T12:55:41.000Z"05398b402a442a6e6f832fa13a552872"142721STANDARD109/Guideline336.pdf2016-11-27T12:55:43.000Z"59757a602e7a3493c2b0b01cb44c5200"78943STANDARD109/Guideline340.pdf2016-11-27T12:55:43.000Z"96b4c12c44c949b435faf30634259d35"167174STANDARD109/Guideline346.pdf2016-11-27T12:55:44.000Z"3cf1a53cf960ed916f1a387592db2e4e"35495STANDARD109/Guideline355.pdf2016-11-27T12:55:46.000Z"a0e2ec9650e1ab1e58c05e3e095825c9"625064STANDARD109/Guideline356.pdf2016-11-27T12:55:46.000Z"b76016aa03f3495282d0672af4c6a2e4"35599STANDARD109/Guideline372.pdf2016-11-27T12:55:48.000Z"c00cf66605470cf7a20657fbe4cd39dc"383127STANDARD109/Guideline373.pdf2016-11-27T12:55:48.000Z"0cf82c93fba02e7df8d9128ea386579e"356137STANDARD109/Guideline392.pdf2016-11-27T12:55:50.000Z"c870f82ba55413702f36a1782d04ab8d"121234STANDARD109/Guideline401FM.pdf2016-11-27T12:55:51.000Z"6a8b4519308ce41674d287ce65fa9c56"211421STANDARD109/Guideline431.pdf2016-11-27T12:55:57.000Z"598d69da8d7cf34ca4d5608efc7b72db"395568STANDARD109/Guideline433.pdf2016-11-27T12:55:57.000Z"44e47a4965322d75050fc18f5addcdfc"955157STANDARD109/Guideline44.pdf2016-11-27T12:55:59.000Z"0cde1d59e2e010e1eb6663fcf40e3314"30788STANDARD109/Guideline45.pdf2016-11-27T12:56:01.000Z"0e19c8e8cd6184d44d3dac14a121b1fe"30780STANDARD109/Guideline49FM.pdf2016-11-27T12:56:06.000Z"99fa85c0f2103320145f7eb51624a344"157308STANDARD109/Guideline50FM.pdf2016-11-27T12:56:08.000Z"9cf2d0b8e6b525321d2ddac4d4e97f80"111038STANDARD109/Guideline523.pdf2016-11-27T12:56:10.000Z"acd739b345fd7b9a9e5a3e2bf5e20053"617388STANDARD109/Guideline542.pdf2016-11-27T12:56:10.000Z"9949484714fe4f6fd71f4de2838c6b51"251716STANDARD109/Guideline548.pdf2016-11-27T12:56:10.000Z"033388d78a40b5a5fbb24c4f27493cbb"175720STANDARD109/Guideline55.pdf2016-11-27T12:56:11.000Z"452ee012d8d3f546734bfe8df384991b"68928STANDARD109/Guideline555.pdf2016-11-27T12:56:11.000Z"4713b9b5d1decef153c7ae8c2f1d9521"217148STANDARD109/Guideline6.pdf2016-11-27T12:56:12.000Z"bca44ddeaab90094f782036dd68096c8"3294711STANDARD109/Guideline64.pdf2016-11-27T12:56:18.000Z"316c7d31887e2856dc8e07b49655e178"581376STANDARD109/Guideline641.pdf2016-11-27T12:56:19.000Z"d4fb3660b6bcd1fab5b5b786a45bcfe1"78954STANDARD109/Guideline642.pdf2016-11-27T12:56:19.000Z"fe788767bd508bd99e445430a2ac7289"175352STANDARD109/Guideline651.pdf2016-11-27T12:56:20.000Z"3b9b1500342103f52b87259b05db0f59"206058STANDARD109/Guideline652.pdf2016-11-27T12:56:21.000Z"0eb553c0f9f4f2934de6267cc6f08fe6"93551STANDARD109/Guideline654.pdf2016-11-27T12:56:21.000Z"30c0dd71b16dcfb9dfde459cbfc53922"698369STANDARD109/Guideline655.pdf2016-11-27T12:56:22.000Z"c141e89b13895c259db295b4ea33cf8d"76509STANDARD109/Guideline657.pdf2016-11-27T12:56:22.000Z"2bb9d40ef747f47eb48adfb273de73a7"207801STANDARD109/Guideline664.pdf2016-11-27T12:56:23.000Z"7c0167fb6b0b985b0639deb5b355d6ec"222037STANDARD109/Guideline670.pdf2016-11-27T12:56:24.000Z"51463d94d37b1434b99a4efa8e6804a8"89223STANDARD109/Guideline696.pdf2016-11-27T12:56:26.000Z"1338410161b91f3dc74d1326666c0945"378194STANDARD109/Guideline718AA.pdf2016-11-27T12:56:28.000Z"9e5df0a5180decb438b000ece3919829"78769STANDARD109/Guideline719AA.pdf2016-11-27T12:56:29.000Z"6f3a87ec5213a771983d25e7d4b2eb99"87709STANDARD109/Guideline720AA.pdf2016-11-27T12:56:29.000Z"739735e85dbc2e31c93cd5f635efaa08"61433STANDARD109/Guideline722AA.pdf2016-11-27T12:56:29.000Z"1febe87e7f0fdadb530e6ff11fbb4cc9"61722STANDARD109/Guideline732.pdf2016-11-27T12:56:31.000Z"4b6a719f9b3974d384c0e4c660f088dc"75344STANDARD109/Guideline734AA.pdf2016-11-27T12:56:32.000Z"5474547ccbbc9aa20588d064eb162c71"36082STANDARD109/Guideline74.pdf2016-11-27T12:56:33.000Z"fe5d7990d57b710f337e0285b996713c"110643STANDARD109/Guideline759.pdf2016-11-27T12:56:37.000Z"bbc9d98bb439c14c8fa5c15038dfbe8e"188273STANDARD109/Guideline769.pdf2016-11-27T12:56:40.000Z"677605e5b7ceff0f50dea2abd2fe408e"201044STANDARD109/Guideline777FM.pdf2016-11-27T12:56:43.000Z"09c2c219aeddfe7815e0c80d224b158b"137552STANDARD109/Guideline781FM.pdf2016-11-27T12:56:43.000Z"1ce66f7321667ff0dfbfbc7a85e9d99b"105003STANDARD109/Guideline785FM.pdf2016-11-27T12:56:45.000Z"71d5ade9b4e3d8ff9dfb3f4988159319"240982STANDARD109/Guideline787FM.pdf2016-11-27T12:56:45.000Z"d1ce1986242a724a4a08af1a1eeb3733"235122STANDARD109/Guideline789FM.pdf2016-11-27T12:56:46.000Z"14dcec2e384814bf292b4d877d2f0c46"143188STANDARD109/Guideline790FM.pdf2016-11-27T12:56:46.000Z"447c377d91babca57e34fcce9f9046b5"154012STANDARD109/Guideline791FM.pdf2016-11-27T12:56:46.000Z"6c9bc5566f282471cda448a9444d25c4"229805STANDARD109/Guideline794FM.pdf2016-11-27T12:56:47.000Z"1d50c14404a0685539548b8920eec5f6"278037STANDARD109/Guideline795FM.pdf2016-11-27T12:56:47.000Z"96d1ad0eb37d02f4693cb6f3e4a60c67"153432STANDARD109/Guideline798FM.pdf2016-11-27T12:56:47.000Z"73810a96a9f6aac58782b63d08c28e49"155910STANDARD109/Guideline799FM.pdf2016-11-27T12:56:48.000Z"182345340ef695e57f03114fdae22e1b"147758STANDARD109/Guideline806.pdf2016-11-27T12:56:49.000Z"54ca83e6fbc0b9d63f81fd3a20d6e015"257578STANDARD109/Guideline807.pdf2016-11-27T12:56:50.000Z"fa3de54a5af56b7755f00f3570462a9e"693496STANDARD109/Guideline85.pdf2016-11-27T12:56:51.000Z"091bbe6124e6f9a955c0662601eef56d"25369STANDARD109/Guideline90.pdf2016-11-27T12:56:52.000Z"4ec7b5a42dcbd9cb0e384beebc5f2360"153193STANDARD109/Guideline91.pdf2016-11-27T12:56:52.000Z"cc06960e31208eb16cb62308225127d1"69755STANDARD109/Guideline92.pdf2016-11-27T12:56:52.000Z"6d8e4ff70ddbc3ff2902f886a7622b71"420395STANDARD109/InductionbookletforFebruary2016.pdf2016-11-27T12:56:55.000Z"41f38de0b8d00ab29ce81dd5e5df6187"1841602STANDARD109/JUNIORDOCTORINDUCTIONPACK.pdf2016-11-27T12:56:56.000Z"bdd4946b4e062460be92d99107244b89"562136STANDARD109/acrobatdocumentpaedssepsistoolsept2016.pdf2019-02-28T11:25:48.000Z"322f98c62dbc6c943536dbe4bf11f671"140764STANDARD109/approved061218234633wzz19912.pdf2019-02-28T11:26:14.000Z"561370f81e7d1fd0044c5ba2ccc61ed7"3095066STANDARD109/bhtpol182.pdf2018-10-12T15:27:21.000Z"c6696361786e70db31fbcea2cee5c95a"781650STANDARD109/bhtpol206professionalpersonalboundariespolicyv1.0rvw092017.pdf2016-11-27T12:55:00.000Z"8c63c9dc05fcdcb80a2f06e68382be9b"457423STANDARD109/fqpatientsheetfinal.pdf2019-04-03T08:58:23.000Z"a8ce2649101c3570555d2ba39623cec7"166581STANDARD109/guideline100.pdf2018-04-30T14:34:45.000Z"2b11f3bf851ed8eed7437b901c1f5e36"56187STANDARD109/guideline102.pdf2019-02-12T12:45:58.000Z"4d552590ebd66547cf190c204c748262"47684STANDARD109/guideline105.pdf2017-06-21T12:24:18.000Z"7b362e4f21036248cc491d0205d2cb14"548625STANDARD109/guideline107.pdf2017-09-05T10:17:39.000Z"7f9e484b487d70c78a7d8de68617ca63"622207STANDARD109/guideline108.pdf2019-01-30T10:30:29.000Z"afc476935dad7b24d65a43e6b94b4a60"123559STANDARD109/guideline111.pdf2019-02-27T17:18:45.000Z"d472211e02c69bf15c0bbaee8fd4b605"282786STANDARD109/guideline118.pdf2019-02-19T10:20:21.000Z"779565f7963cd65bfb17055e477eab58"183793STANDARD109/guideline119.pdf2018-03-28T15:03:06.000Z"635740db40851b3796ad03f99e94ce0f"113925STANDARD109/guideline12.pdf2017-06-30T09:03:35.000Z"e360167e15b703746e83536a77600776"812137STANDARD109/guideline120.pdf2018-08-22T15:29:07.000Z"984ee43703daa7f57fd757eba0d324c2"118556STANDARD109/guideline125.pdf2018-10-09T10:44:18.000Z"b0c331b0ab605d2c50f801615df2836f"91619STANDARD109/guideline13.pdf2017-03-21T16:43:50.000Z"a91725347f978ee5e88d28f9b5964687"222242STANDARD109/guideline132.pdf2018-09-28T15:52:03.000Z"1a17251f1437b344a0bb3cea64d485d4"132472STANDARD109/guideline134.pdf2018-04-27T08:28:45.000Z"790ad43eda774a17cf02b1178d9bc71b"344442STANDARD109/guideline135.pdf2017-08-24T10:41:22.000Z"53958d54d12bb401b1d17d4035fc92d0"111857STANDARD109/guideline136.pdf2019-01-08T16:25:55.000Z"8672df088483b76f2dc97d72da98f447"112679STANDARD109/guideline138.pdf2019-04-23T11:26:15.000Z"3b06a48f08f1dd477cbec4d6e764d306"115949STANDARD109/guideline139.pdf2017-11-13T11:26:31.000Z"c776daa57c334e4e5260ff39cc510d50"499217STANDARD109/guideline140.pdf2019-02-26T12:34:22.000Z"9f1574b8748c2c7a32ce364f21f8f3d8"786307STANDARD109/guideline141.pdf2018-02-19T16:20:53.000Z"767b7393b06bfc1b57e683e1d5bf6720"253660STANDARD109/guideline143.pdf2019-03-07T13:54:35.000Z"34cd427183f23d3b6ab0911119cc8e01"125952STANDARD109/guideline147.pdf2017-05-02T12:35:47.000Z"94887d2ecd3c323ccad4fcc2aa358a0c"106595STANDARD109/guideline149a.pdf2018-05-11T15:53:41.000Z"49214c3c0520e009b209aaebf76e223c"671292STANDARD109/guideline149b.pdf2018-05-11T15:53:55.000Z"5f81fdd84dc31ca3dd8a3cf32d6b2701"669656STANDARD109/guideline14e.pdf2017-06-29T10:23:51.000Z"e9a9f062ebc075f967d0f2e88238492e"202674STANDARD109/guideline150.pdf2018-05-11T15:54:30.000Z"742a993d8d6bf662f30ec109b3e82200"99494STANDARD109/guideline152.pdf2017-09-22T15:18:36.000Z"8983ebda2d93708917f433c888b361f7"145877STANDARD109/guideline153.pdf2019-01-25T16:26:02.000Z"214014a28ac778ed463075833408c516"1041681STANDARD109/guideline154.pdf2018-10-11T15:30:32.000Z"d23eacc41a61079b648003ba1b9ba16f"149327STANDARD109/guideline155.pdf2018-06-18T11:00:41.000Z"44b8d22fa522832d0c4742c89734c260"234398STANDARD109/guideline157.pdf2018-05-25T14:03:37.000Z"510f9e023e0051d31950cc5cb858183d"110484STANDARD109/guideline159.pdf2019-04-29T13:07:16.000Z"bf7afe91fdaa20c0a811fcd8eeaf2467"25156STANDARD109/guideline160.pdf2019-04-01T14:31:13.000Z"7d2a3bd0dd7e3754d2ee115319abb186"134117STANDARD109/guideline162.pdf2019-01-15T10:02:46.000Z"1677bb1fde7cccfb66a5acee19caf644"103063STANDARD109/guideline163.pdf2017-07-05T12:02:56.000Z"3ac16404ec7b1603b36530432cd07b47"199176STANDARD109/guideline164.pdf2018-12-06T16:10:48.000Z"41d2e30fd68ad1abe1d487e62d295a1e"106597STANDARD109/guideline16diarrhoeaininpatients.pdf2016-11-27T12:55:13.000Z"aca4c38b4f75a4bf22e9bdec9a0cb96f"138924STANDARD109/guideline17.pdf2017-09-26T10:54:40.000Z"2d652b5ae0ce06d6150c6ca9c80ebbf9"146942STANDARD109/guideline173.pdf2018-05-30T11:05:31.000Z"ae333a1155753cef7e5645ef65246adb"175825STANDARD109/guideline175.pdf2018-02-27T16:48:47.000Z"dd0973b30d316635e47079621c9c5279"172777STANDARD109/guideline177fm.pdf2017-12-20T16:21:02.000Z"7859bf2a75938afa29d0628919963aee"175140STANDARD109/guideline178.pdf2018-08-30T14:38:00.000Z"a298923130dd9834dccdcf8545ba4a0a"163122STANDARD109/guideline179.pdf2018-08-20T12:51:03.000Z"ec717f0c1b39ea32095e9b37f85a4082"155079STANDARD109/guideline18.pdf2018-12-31T08:22:09.000Z"231f2753328103bf0ffc9220d6a2bced"61348STANDARD109/guideline180.pdf2017-05-02T10:37:33.000Z"fd481ce7961b1ba4084bf87b2905f415"161270STANDARD109/guideline181.pdf2018-05-30T12:32:38.000Z"721836d3b9c35a1b937a3b0acd86105f"102698STANDARD109/guideline183.pdf2018-09-06T07:47:54.000Z"325ad3e77a10d0265a98a04fecf0cff4"103374STANDARD109/guideline185.pdf2018-02-19T16:49:13.000Z"d2114144d36c72189c7ac94b09fd6e13"203015STANDARD109/guideline187.pdf2019-05-07T10:35:10.000Z"330018d066dd961d32682d2a558584e9"102799STANDARD109/guideline19.pdf2018-09-20T13:37:03.000Z"b536e85ac4e85a35e901cb5ac6ffb43b"470089STANDARD109/guideline190.pdf2018-02-13T12:00:39.000Z"60c7fea86d412620b4f9bc447de80a3d"122281STANDARD109/guideline192.pdf2018-02-13T11:59:42.000Z"15856f84d21aa96b853b48a3e9f98810"119215STANDARD109/guideline196.pdf2018-11-22T12:11:26.000Z"126a599effeb320ff5a4a707a38fbf7a"392797STANDARD109/guideline197.pdf2017-08-30T14:43:17.000Z"95b99671e323f6a8bb622ee6bbc6e244"649354STANDARD109/guideline20.pdf2018-12-28T16:52:03.000Z"439e5a7650ddcae031a6cbd373e57f4a"476941STANDARD109/guideline202.pdf2019-02-27T09:07:21.000Z"d3367289196e5e783d93cb4f388b6443"364095STANDARD109/guideline204.pdf2018-07-31T12:25:43.000Z"f96757909b030322dd1f835a4eb0b024"170447STANDARD109/guideline207.pdf2018-06-15T11:49:40.000Z"b24874fa9a47f24aad9be855b8e16ddb"187113STANDARD109/guideline21.pdf2018-04-11T15:28:38.000Z"57137b87309e9c508ae24a0747f87fd5"206402STANDARD109/guideline211.pdf2018-11-15T15:21:13.000Z"09b417387bc82ef176c32619626f8856"123190STANDARD109/guideline213.pdf2019-01-09T15:33:24.000Z"0657c2bc5527482916aadcc8ad2919e2"2717401STANDARD109/guideline214.pdf2018-12-03T11:35:08.000Z"cd449a3f4bad13b4b8b41c1d4987bd37"451660STANDARD109/guideline215.pdf2017-07-31T09:44:46.000Z"3e4a15069d4756ffb6a643d81938d401"512914STANDARD109/guideline216.pdf2019-04-23T11:29:06.000Z"65730c9c52b2b1c3689b483af29e22f0"217653STANDARD109/guideline22.pdf2019-03-27T12:24:39.000Z"5d7ee553284e68f8adba6363292938e9"101161STANDARD109/guideline225.pdf2017-06-26T10:04:47.000Z"cdd01cc0828a2c603035ce18a9ad1042"190748STANDARD109/guideline226.pdf2019-04-17T10:18:01.000Z"b860b1a5d484c97e9d47ee0cdbf0a57c"116313STANDARD109/guideline229.pdf2018-08-16T11:59:25.000Z"9fb67d5f85bf6c6585e39583c2f9c1b8"795148STANDARD109/guideline230.pdf2018-04-18T12:45:22.000Z"237dbe0508ca742ff5751ace61d649ef"180169STANDARD109/guideline231.pdf2018-04-18T13:45:56.000Z"889a1673dde1078770c99b3c4fb2366e"125228STANDARD109/guideline232.pdf2018-04-18T14:18:56.000Z"2f69e9304a6a3a4b5f66b73f138c0b92"128781STANDARD109/guideline236.pdf2018-09-28T15:55:16.000Z"ed3786a2039b2d59ecd63378606a6d5e"340992STANDARD109/guideline237.pdf2018-04-26T09:01:08.000Z"6dc4d9697a4d2208f5814da6be16233e"103232STANDARD109/guideline238.pdf2018-06-20T13:21:57.000Z"bcde15b751b0757cbc13c79eaea5c0b9"301610STANDARD109/guideline239.pdf2019-03-04T14:49:57.000Z"3a5eb1bde44b10fc5b29390981df18da"372644STANDARD109/guideline24.pdf2019-05-22T07:35:26.000Z"12e460bd1568972f569aa42034aab032"126058STANDARD109/guideline241.pdf2017-09-15T11:31:10.000Z"fab9d20b227e646f052910733b3217ff"236632STANDARD109/guideline242.pdf2019-05-21T12:12:01.000Z"6c07a305c285dd3562a101c36f726682"210365STANDARD109/guideline244.pdf2019-01-31T13:17:11.000Z"f64fc697684d65383fbe8be0759bfac1"188205STANDARD109/guideline245.pdf2018-09-06T07:49:23.000Z"cc81ac505351cad502cebf770af21174"176970STANDARD109/guideline248.pdf2018-11-26T16:28:23.000Z"fda48f1f05dbd92b6cc795fdbee75922"121856STANDARD109/guideline249.pdf2018-06-20T13:21:37.000Z"4e0f1cb3b054aae1d8782953159a88e8"258739STANDARD109/guideline250.pdf2018-08-20T13:35:06.000Z"8d9475b8ff880855e893701ab132118d"105635STANDARD109/guideline252.pdf2018-08-20T14:00:00.000Z"97eb956d3b517bfa1ecee9ca8e7166ab"129063STANDARD109/guideline253.pdf2018-08-20T14:26:24.000Z"26c2c52f38a94622cc19cbbdf4885991"166444STANDARD109/guideline254.pdf2018-08-20T14:50:08.000Z"60d9370f131a46b0ad75bcf2766c5348"111308STANDARD109/guideline255.pdf2017-07-31T12:12:12.000Z"2db0d161a9df3b391db21b48e68dae3e"100752STANDARD109/guideline256.pdf2018-01-16T16:54:13.000Z"c40c2024b8633853ecc37e04ea02b73a"147571STANDARD109/guideline260.pdf2018-08-20T15:30:23.000Z"751b38c8a86df13ff399e247506eed49"110063STANDARD109/guideline263.pdf2019-03-12T13:15:17.000Z"9bba005eada6f7d1d897b30592d2debe"886547STANDARD109/guideline264.pdf2018-06-18T11:01:05.000Z"c03d6515e21580095eab9087507f27ab"152916STANDARD109/guideline265.pdf2018-10-11T14:40:34.000Z"c5eef4383b0f4d6b1f7a4b5d8a1caa59"223645STANDARD109/guideline266.pdf2018-10-11T14:41:02.000Z"09b6595ef11efec264ffb325133b2596"364620STANDARD109/guideline269.pdf2018-10-05T12:47:09.000Z"0dd3e5a87fa3ad19042d84449ac91cce"566047STANDARD109/guideline270.pdf2017-06-28T11:52:55.000Z"ff69aed172d915746215b889a25f1f0b"138558STANDARD109/guideline273.pdf2019-02-26T16:22:36.000Z"d0537c66dca449b0487f007c4f158d80"378940STANDARD109/guideline274.pdf2019-05-01T07:28:51.000Z"a822dfc28d069416001b404f8f75d873"42198STANDARD109/guideline278fm.pdf2017-04-28T11:05:11.000Z"8be80618052076098c8335cbad4a6f31"139747STANDARD109/guideline279.pdf2018-04-30T08:18:14.000Z"791ee338c6e67d4a58a0661d60146fa0"629205STANDARD109/guideline281.pdf2019-04-11T09:58:36.000Z"a61326268a83db376735c3c7f57f0f41"213347STANDARD109/guideline283.pdf2018-11-12T09:24:04.000Z"09c6f8e107fb5913ffcc3cec25dc3eb3"179222STANDARD109/guideline286.pdf2017-03-22T09:55:03.000Z"8a74ca8fe14bb148f50078dfb4f93580"2597156STANDARD109/guideline289.pdf2019-05-17T13:39:42.000Z"ca66c03a6492c32cd146e1222df081d2"251888STANDARD109/guideline291.pdf2019-04-12T13:34:46.000Z"fb9c72381087e68b076ceabd3faa4b3e"181826STANDARD109/guideline292.pdf2018-01-16T16:52:18.000Z"7180a458f1eaa4d0df8605ea5670d80d"122037STANDARD109/guideline294.pdf2019-05-13T11:21:08.000Z"70b91d1a803540775bef058510538e74"109768STANDARD109/guideline296.pdf2019-02-15T16:53:17.000Z"6a835bde56455a4e2b8a59950c4f5341"208632STANDARD109/guideline297.pdf2018-03-16T16:33:12.000Z"7809da18fc55ae4aae725b4015c53c19"3766723STANDARD109/guideline300.pdf2018-09-24T14:17:13.000Z"6fc7a39262d1f04087544936f6e9abd5"628921STANDARD109/guideline301.pdf2018-10-11T15:45:17.000Z"f7347a1a3383f3b47536656c2e73b300"1752124STANDARD109/guideline302.pdf2019-03-07T14:05:51.000Z"9c16086d3e4a300432435bb6ff464a56"238598STANDARD109/guideline303.pdf2018-07-10T14:18:40.000Z"439ba08d2791692afcf40caacecbb50a"25495STANDARD109/guideline31.pdf2018-06-13T14:00:44.000Z"4792c59381cb2e37b114dc1dd11c0c4d"62638STANDARD109/guideline310.pdf2019-05-22T13:12:32.000Z"ba4cdafae9e6c8a078396de7e2f94632"140872STANDARD109/guideline317.pdf2018-04-25T15:02:08.000Z"4a86f33daf1095a16a846128ce928aa3"133462STANDARD109/guideline32.pdf2017-03-21T14:41:57.000Z"55ee828218ba8704310b364c7d65ec84"434108STANDARD109/guideline320.pdf2018-10-24T10:26:32.000Z"85da12afccfc7ad1505adccb419c4a13"188241STANDARD109/guideline321.pdf2018-09-21T09:04:54.000Z"b46cae6138a4884a1619b1a4abb0140b"98784STANDARD109/guideline322.pdf2018-04-13T10:30:51.000Z"3474de94d176fdea0436143202699869"110550STANDARD109/guideline324.pdf2019-02-05T14:51:54.000Z"b64b2e97e2bab3a45dc6d7928f3fd65b"450988STANDARD109/guideline325.pdf2017-03-22T09:39:14.000Z"f9c4df06f390e90c0414b9db0ad7f4ee"26979STANDARD109/guideline326.pdf2017-06-28T15:21:46.000Z"459a5fab20cfc9bef1d5368edde86f14"196753STANDARD109/guideline327.pdf2017-08-10T10:28:50.000Z"740440df7ea6e31f410be21e3230b3c5"279563STANDARD109/guideline328.pdf2019-04-23T11:32:37.000Z"2d38c9402dbdcdaa9c695a8f321e6394"190571STANDARD109/guideline329.pdf2018-03-15T17:00:23.000Z"21e087d41074575b1a7c2488eb39ebf4"111780STANDARD109/guideline33.pdf2018-02-13T11:47:42.000Z"86a708058e91380cd8b2c59236807100"106159STANDARD109/guideline330.pdf2018-10-22T15:15:24.000Z"90c8e1edc962dc05fd083783678af1c3"147126STANDARD109/guideline332.pdf2018-10-22T15:16:41.000Z"e963f9b4ab9f314f1ffafc577aac4226"1814323STANDARD109/guideline333.pdf2018-10-22T15:17:12.000Z"2130ee2de3d43b65e4fa283c0d1cc6a4"275363STANDARD109/guideline334.pdf2019-04-23T11:27:00.000Z"ff2410869d582b1c9315538b3bb60868"1643623STANDARD109/guideline337.pdf2019-04-23T11:27:43.000Z"c4d49e8574e1f15cfb8be864e31b7e78"189275STANDARD109/guideline341.pdf2018-10-22T15:13:32.000Z"cd1e6a776db39faf24a099cf70f687da"201445STANDARD109/guideline343.pdf2019-04-12T13:33:48.000Z"b26a6bc76b67a155d5eb6abb36244721"1676392STANDARD109/guideline348.pdf2017-05-22T10:40:36.000Z"f8d9ab5b528dae620739eab9adbcbd33"136128STANDARD109/guideline349.pdf2018-11-13T13:48:26.000Z"2920c1fec3bcfcb0e3fdaf6e5fa3faa6"148288STANDARD109/guideline34fm.pdf2017-04-12T13:45:54.000Z"aef0fd8e9f767cdc02e275a015937b90"1566937STANDARD109/guideline35.pdf2018-04-18T10:28:37.000Z"898237ff2db910c4d6f0be27385a338c"126860STANDARD109/guideline350.pdf2018-11-15T11:41:11.000Z"a701403591d41a897d70b7d282b75e9a"199705STANDARD109/guideline354.pdf2018-04-18T14:58:39.000Z"cf0f6f0b79559b5336f8992f89ef0513"157369STANDARD109/guideline357.pdf2019-02-01T11:16:07.000Z"8e7f1998da457c9ab3b9f0ade245260f"123942STANDARD109/guideline36.pdf2018-09-06T07:51:32.000Z"bdffb19160724adcccd956d927cc8dbc"747271STANDARD109/guideline361fm.pdf2018-10-08T10:29:09.000Z"9e3465ea49050393bef5b2ae0c9b9d6f"201941STANDARD109/guideline362.pdf2019-05-21T12:29:23.000Z"25e2c227a41db6fdfcd594566889e6b9"632811STANDARD109/guideline363.pdf2019-03-29T15:53:35.000Z"a46ed4d97210f59cdcceeaf9083b40fc"194556STANDARD109/guideline367.pdf2019-02-15T16:55:54.000Z"3f2c9b5212f85d403217e30fa692575b"108873STANDARD109/guideline368.pdf2019-02-15T16:56:02.000Z"cf2d91aafabd28318fb9e769d37fd08a"92351STANDARD109/guideline370fm.pdf2018-09-10T08:11:28.000Z"32e686041cec8270c80c76dc20c5e86d"98325STANDARD109/guideline376.pdf2018-09-28T11:04:35.000Z"e3630cf182f3c065b7ead2b4ff721bcf"356983STANDARD109/guideline377.pdf2018-05-11T10:10:21.000Z"2de2181ac2bd2b3008738c0aef0dfe7b"37918STANDARD109/guideline379.pdf2017-03-21T16:11:23.000Z"28291780c02030f901c8a7a0701c30e6"369238STANDARD109/guideline38.pdf2018-02-13T11:48:47.000Z"0d9f98b3f73c750b54be678d558525d3"116322STANDARD109/guideline380.pdf2018-06-12T15:44:23.000Z"efaf57f0295c6f11c8c36111f8e70a73"195592STANDARD109/guideline381.pdf2018-06-12T15:43:36.000Z"e513b23e554657b27fd821b4e550aaab"204402STANDARD109/guideline382.pdf2017-08-01T11:20:14.000Z"94d984780a9077d398e517249dcef80d"137812STANDARD109/guideline383.pdf2017-03-22T12:52:48.000Z"78b11bf8c58fb306a351bd7b33c22f2c"206140STANDARD109/guideline386.pdf2018-06-14T14:24:05.000Z"bf6abd94a0a3137e5874429fc51d9804"1726404STANDARD109/guideline388.pdf2017-09-22T15:19:58.000Z"ac40d75c64174b1107fdf91b3c506322"610391STANDARD109/guideline389.pdf2017-11-17T11:17:55.000Z"a13e2017580b16852d7ca38a15caaab2"185878STANDARD109/guideline39.pdf2018-09-28T10:25:31.000Z"92948e1d184819e9292cd60acbb4f4ca"206423STANDARD109/guideline390.pdf2018-10-24T14:43:35.000Z"56efe1899e77d8aa8b1602470cab16b0"174649STANDARD109/guideline391.pdf2018-02-05T16:22:54.000Z"33a847721d6ffa9a987334bb5c2f1e5d"167405STANDARD109/guideline393.pdf2017-01-27T16:28:22.000Z"b7916dd406d08e15a0bef19d6ce320a2"181605STANDARD109/guideline394.pdf2018-04-30T13:06:31.000Z"62e7d4a0941ce01da20bbf9852f67a1f"436322STANDARD109/guideline395.pdf2018-06-07T15:47:06.000Z"d81b6f6674e926687cadf3fcdb33f71f"1829007STANDARD109/guideline396.pdf2018-03-16T16:33:55.000Z"d4a934c029e86b12c8d4c279a9e05d65"2778551STANDARD109/guideline397.pdf2018-04-30T10:38:45.000Z"1182b2602a8ffa896e11b9309331db2e"260280STANDARD109/guideline398.pdf2017-02-10T11:47:31.000Z"640b16e533803dd607b6caa0cd99496e"191688STANDARD109/guideline399.pdf2017-11-15T16:48:22.000Z"97aa9210030c46f8aebc28ff27c0b79a"201437STANDARD109/guideline40.pdf2019-04-11T11:16:58.000Z"87e98c97cbc69059640d82c047a1fa8e"457790STANDARD109/guideline400.pdf2017-03-22T10:04:04.000Z"0632cee5d79baa702365cb85aa4c0a14"303324STANDARD109/guideline402fm.pdf2017-12-05T15:29:44.000Z"cc4df0bdc347113b3ee7300f7968d848"387197STANDARD109/guideline403fm.pdf2017-12-05T16:25:09.000Z"63b097f7ba292c242c601547e0170640"499934STANDARD109/guideline405.pdf2017-07-31T12:10:00.000Z"64401690058b652c43cbb1fd577e8dc8"227033STANDARD109/guideline407.pdf2018-12-10T08:57:05.000Z"b1abf8b43a8e18ad04e191be4c71e131"361112STANDARD109/guideline409.pdf2017-03-21T16:59:48.000Z"b23256e65d5991ff040c392dc439c5ca"233407STANDARD109/guideline41.pdf2017-08-21T14:48:55.000Z"4af802a7e3609a6d737d4c329e354880"100796STANDARD109/guideline410.pdf2019-03-08T13:22:17.000Z"21e93e29c8b911b47b5255af2571934d"929700STANDARD109/guideline411.pdf2018-04-03T11:24:54.000Z"89942d1f5a7670a7419ff0eb8aab8cc1"148413STANDARD109/guideline412.pdf2019-04-30T11:10:54.000Z"aca73942a0398203c2376ccf2aacf268"244310STANDARD109/guideline413.pdf2017-05-22T10:54:24.000Z"2f6313039534a5240cb49a7b16237b6a"248250STANDARD109/guideline414.pdf2018-02-05T16:09:40.000Z"4f9d0086823898e274fc89937ca4798b"231439STANDARD109/guideline415.pdf2018-07-17T16:09:02.000Z"b69088b8651bc3eb4901cd19bc6ddd63"286748STANDARD109/guideline416.pdf2018-04-03T15:48:47.000Z"59c792983857770aa14bbad678b0ab91"407392STANDARD109/guideline417.pdf2018-10-02T10:21:05.000Z"4204c2295baabfc3f0eb47530f442b98"326141STANDARD109/guideline418.pdf2019-05-17T13:32:10.000Z"b52f37802b33b8720122469904d8c713"804933STANDARD109/guideline419.pdf2018-06-13T10:22:36.000Z"677d00fb28dcee5fb7c93a87255b200a"213416STANDARD109/guideline42.pdf2018-12-31T14:07:09.000Z"cfd8987c1c3bd67f1cab728d351701a6"155227STANDARD109/guideline424.pdf2018-03-15T10:32:36.000Z"99076da9c990112cfca491048f998b74"140891STANDARD109/guideline425.pdf2018-05-02T15:35:17.000Z"68efa5de007fbafcdb8c71f21721204c"1023952STANDARD109/guideline426.pdf2018-02-05T16:18:45.000Z"e28d16e6ca33f75bd0837a2c2dbb24e9"508327STANDARD109/guideline428.pdf2019-03-13T16:44:53.000Z"952d928b5f4935738e4db165afbba52a"598713STANDARD109/guideline429.pdf2018-11-19T15:15:56.000Z"b4ec38e6cf1bfeee5ff3e7ecffaa44f6"1599432STANDARD109/guideline430.pdf2018-11-13T09:55:39.000Z"d4cf2bb68b93f4440d057ebb3685f8b5"294606STANDARD109/guideline431.pdf2019-03-13T15:34:31.000Z"c76a85b43807b12ca2f873c618c792a0"395469STANDARD109/guideline432.pdf2019-04-17T12:13:30.000Z"441fb55c2518cb3ca6ad6b68e25a316b"135118STANDARD109/guideline433.pdf2017-05-04T11:07:26.000Z"d36843aec96d4999227befb5f4e7fcab"954885STANDARD109/guideline434.pdf2018-10-26T13:08:39.000Z"4940b0a8730b471774d826afcf8cdb91"831019STANDARD109/guideline436.pdf2018-02-05T16:27:22.000Z"b952af654ac47c5d9fb223e5973df7d6"409656STANDARD109/guideline438.pdf2019-04-24T15:29:34.000Z"f2d80d8b02f99ac87766176869b77fa9"318212STANDARD109/guideline439.pdf2019-01-29T10:33:52.000Z"45def34982529118af46945288646e74"264802STANDARD109/guideline441.pdf2018-12-27T16:54:02.000Z"c8ec40ba93cb834f260451bdc6c496a2"136210STANDARD109/guideline442.pdf2019-02-08T11:55:30.000Z"9b6798981ab6385a25d52192efcfeefb"291670STANDARD109/guideline443.pdf2019-03-06T11:58:30.000Z"03b06c1e211392c9de51a4ce63fdb030"439893STANDARD109/guideline444.pdf2018-05-23T07:44:23.000Z"c7f14eca40563892fa893af074704ecb"261593STANDARD109/guideline445.pdf2018-12-31T14:55:49.000Z"1b3707c2b190635f5d586e35e1b6fc20"359698STANDARD109/guideline446.pdf2018-05-21T15:05:51.000Z"0200b94509a30212bedd6cb550a715b5"481900STANDARD109/guideline447.pdf2018-04-03T15:49:32.000Z"1e71381fafb317d2d587796e2ba36c1b"366766STANDARD109/guideline449.pdf2018-02-05T16:41:29.000Z"96db151adc78a05e562bccf3653e697d"2222735STANDARD109/guideline450.pdf2018-02-05T16:19:13.000Z"a28a32cd063e809aaef31085fa8966f3"511594STANDARD109/guideline451.pdf2018-12-21T12:34:02.000Z"ccc329f900da0b937137d3e4b7701f9f"250771STANDARD109/guideline452.pdf2018-02-05T16:14:41.000Z"87b91d8c563b29a5f966593acb0006bb"268450STANDARD109/guideline454.pdf2017-07-03T08:16:33.000Z"a4449a7e4ba7dcbdc25f1f6658697695"525747STANDARD109/guideline455.pdf2018-11-21T08:18:23.000Z"83cb0bba527e171434e32ae440759885"348790STANDARD109/guideline456.pdf2018-12-19T11:12:23.000Z"7b53c2bb867b204cff940851c8fce1dd"1700023STANDARD109/guideline458.pdf2018-05-04T12:41:35.000Z"ed6e7005aa116f8d3625a05dbb7ef7cd"342638STANDARD109/guideline462.pdf2019-03-13T15:33:59.000Z"4417fc32b4f75cabc65072bcabb11da1"275816STANDARD109/guideline466.pdf2018-12-19T09:21:26.000Z"52e604594b4d0e578674ad9f6a89f8cd"246311STANDARD109/guideline467.pdf2018-12-19T09:12:23.000Z"960b91aa005cae8150e51231250ffc84"363340STANDARD109/guideline470.pdf2019-01-28T10:14:36.000Z"46a8a88003d3adf3abe283a54e7a9d64"243008STANDARD109/guideline471.pdf2018-09-20T11:30:57.000Z"3512b0f0d3735985d31266be04300552"527231STANDARD109/guideline472.pdf2018-09-20T11:33:19.000Z"5938429b10d32ee43a2aa72ea5a47577"275521STANDARD109/guideline474.pdf2018-07-23T12:12:09.000Z"928cf993fe1b5219b78b7473e3dbdd29"663215STANDARD109/guideline476.pdf2018-05-23T16:05:49.000Z"2e8dd04fab4e486d9819210c73e73357"143280STANDARD109/guideline478.pdf2018-04-03T13:31:23.000Z"bd3cce06e9b3297e5713d03f7ba32faf"342581STANDARD109/guideline48.pdf2018-08-01T09:02:47.000Z"8b7febdc0f6f98faf2af3f6e298b57fc"295924STANDARD109/guideline480.pdf2019-04-15T08:09:24.000Z"a8025ea220fe83d2e4e58bd6f8ccd123"616113STANDARD109/guideline481.pdf2018-02-05T16:13:06.000Z"9000da0557f9e24a6dbe5cde62c07975"213871STANDARD109/guideline489.pdf2018-10-24T16:03:46.000Z"8bf09236bcbf07a13674cb21749cf61e"389772STANDARD109/guideline491.pdf2017-05-11T08:54:08.000Z"cffa8e8a61fc087ee5adbfcca87c9578"126830STANDARD109/guideline492.pdf2018-12-21T15:23:11.000Z"3d25ed6463a06d099e091f34ffcdc7cf"193692STANDARD109/guideline493.pdf2018-11-19T11:32:21.000Z"c2374cb4e1d90535d3587b67046e7c95"830466STANDARD109/guideline494.pdf2019-01-17T15:22:04.000Z"1a4c4ad9f64e5116456d889ace2824dd"291224STANDARD109/guideline496.pdf2018-08-15T14:35:10.000Z"1ea3b9f71f7313f33d72575c099ea6b9"369287STANDARD109/guideline497.pdf2018-02-05T16:24:28.000Z"44fb0d992c8f8c059e83f4a304977bec"92842STANDARD109/guideline498.pdf2018-02-05T16:16:36.000Z"d0d0f9c32a7481656809e1ee4386fc81"250256STANDARD109/guideline499.pdf2018-03-29T14:43:58.000Z"5a905fba9f8b1aab638c0dc65e99f446"191638STANDARD109/guideline503.pdf2018-09-10T10:11:41.000Z"47c8fb6bdde663ea2852a96930a93b35"125727STANDARD109/guideline505.pdf2018-10-02T10:07:16.000Z"b3dc410d3c1daea0ef2c72795e2f4ebe"478735STANDARD109/guideline506.pdf2019-04-16T11:10:37.000Z"51edf6eadb247be6925ac20c41354462"1106871STANDARD109/guideline51.pdf2018-08-30T11:05:04.000Z"1738080c69a04ac584901107a446e9e4"142237STANDARD109/guideline510.pdf2018-03-15T13:23:10.000Z"c9e7a9eeac65480b8b30e5dbd2fcf71b"221405STANDARD109/guideline511.pdf2017-12-21T10:57:31.000Z"840fdb4ca49a2ef7dec2ee881381b1f0"279638STANDARD109/guideline512.pdf2018-07-23T08:48:17.000Z"7c96c018cb0691eb5733dd1580c66549"853322STANDARD109/guideline513.pdf2018-10-02T10:21:52.000Z"09c97a02ed72af0fcc4202ea03228e7d"302545STANDARD109/guideline514.pdf2019-02-28T17:13:50.000Z"61907c510bb9121c0e960c9904f3070d"338624STANDARD109/guideline517.pdf2017-07-17T12:26:55.000Z"d92106ddf9d72e584cacb758b63c9299"205721STANDARD109/guideline518.pdf2018-12-19T14:26:10.000Z"62b94284accbe6f5a1572141b31a3d2a"1218996STANDARD109/guideline519.pdf2017-03-22T11:08:42.000Z"82f4c7174200b8d4df70c4d2037782d3"168165STANDARD109/guideline520.pdf2019-03-04T10:36:18.000Z"c1fa9d84b6f3f7c7b125c5b0bc6cfcd4"1122668STANDARD109/guideline521.pdf2018-04-09T08:14:02.000Z"c556c7192bf7bf8273aaae0ad62277b5"425928STANDARD109/guideline526.pdf2019-02-01T15:26:35.000Z"856252e0b83ab190949477f08898f609"455714STANDARD109/guideline530.pdf2018-02-05T16:37:51.000Z"86b6ae254fdc9adb4b1e41eabbc06ff7"279554STANDARD109/guideline532.pdf2018-07-19T15:31:03.000Z"9bcd98c4b9b713ccba34ebfd371ebe8c"128173STANDARD109/guideline534.pdf2017-07-20T07:21:35.000Z"1126f6798f5edf4ae526be14913a0604"322337STANDARD109/guideline543.pdf2018-04-13T15:34:55.000Z"8b3ba131c57b8a8f26effd8492c8c15f"512455STANDARD109/guideline545.pdf2018-02-05T16:18:19.000Z"460fa39058735c6bb2b0ac2a5e172b2c"322141STANDARD109/guideline546.pdf2018-10-02T10:21:29.000Z"ad14e15993cce7c5114c721532240e50"597289STANDARD109/guideline547.pdf2017-05-03T11:13:26.000Z"63f443a3763b6d673a2d8b9ee162b390"345748STANDARD109/guideline549.pdf2018-02-05T16:15:25.000Z"11317a9a0430cca64661e2f4d75cf839"145416STANDARD109/guideline550.pdf2018-07-04T14:07:04.000Z"cf74d556a69ca4e4bb933f7210c74258"682531STANDARD109/guideline551.pdf2017-03-21T15:25:30.000Z"e0981f843c574a06b67100bed12eb3ea"242547STANDARD109/guideline552.pdf2019-01-02T15:50:44.000Z"77c508ffffeeb46e94a0b285f56443fc"535354STANDARD109/guideline558.pdf2017-02-10T11:55:12.000Z"9c8857f21cbeda42486a20c251cf9fc0"194932STANDARD109/guideline56.pdf2017-03-22T11:50:54.000Z"ad5d1e376746417a1bcd740de34c1a21"125233STANDARD109/guideline570.pdf2017-03-22T10:29:58.000Z"257df6379b50bbfb90846f746bbcc712"576790STANDARD109/guideline571.pdf2018-04-10T14:57:07.000Z"35085c1f2392682b98e21a91dec04f56"187687STANDARD109/guideline58.pdf2018-04-03T10:46:23.000Z"0ee9c29cf9887c1259eae5a2da16704b"242767STANDARD109/guideline598.pdf2019-02-05T16:54:20.000Z"cb5fc38f760f4a902dd0d4982d7f1945"167672STANDARD109/guideline601.pdf2019-01-17T09:58:00.000Z"4d1dfd394ef48f14dca5a179865b7f02"431375STANDARD109/guideline610.pdf2019-01-31T12:06:39.000Z"d1108dbfe961660ccf3e72d730e04b31"92465STANDARD109/guideline611.pdf2018-05-25T15:51:21.000Z"3e64074e8d58f6d7bbe48a49d6cbdbf0"1208728STANDARD109/guideline612.pdf2018-03-06T14:56:38.000Z"c4669267f4484ce3c13b8d53da4c2e8a"174270STANDARD109/guideline613.pdf2018-07-04T13:48:36.000Z"c9e86a6ec27866790c0da9c22d8e4660"114498STANDARD109/guideline614.pdf2018-04-13T08:44:20.000Z"839cd9c15f67b43b3a6046f53deb61a8"134280STANDARD109/guideline615.pdf2019-02-08T14:15:51.000Z"40e92c465008fde2c69206d975d0e39b"392715STANDARD109/guideline617.pdf2017-11-15T16:25:17.000Z"ab7c849064094ba0fb463b5776da4d0f"144830STANDARD109/guideline618.pdf2018-03-29T14:45:29.000Z"6892d888fe21538ef33b290fb7e7a91b"289123STANDARD109/guideline62.pdf2017-03-21T16:04:26.000Z"1b9bba039615561535c571873561d5ba"620181STANDARD109/guideline620.pdf2019-02-27T12:41:21.000Z"832b7ecd94061525d64a8dbb912dadbe"536168STANDARD109/guideline622.pdf2017-12-29T11:08:59.000Z"f629b2de7bd83af15c48808868815aec"271706STANDARD109/guideline625.pdf2018-08-17T15:56:47.000Z"b1418d3203637def43f432b0227e7241"484054STANDARD109/guideline626.pdf2018-09-20T11:37:18.000Z"443b8b7936b9cd76e3f16c9170675022"510324STANDARD109/guideline627.pdf2018-09-20T11:38:39.000Z"ef42df9c02e931724bc29cfca8aeb326"1041031STANDARD109/guideline63.pdf2018-06-18T12:53:09.000Z"f31d75ed50b70b7ae4489517ee57639a"251805STANDARD109/guideline635.pdf2018-04-03T15:49:05.000Z"0abb619ed20c8464f22434bf4b28c3b8"65871STANDARD109/guideline638.pdf2017-04-28T10:32:55.000Z"1a2fdf0a183a9ef52b4a23233c8d65c6"98621STANDARD109/guideline640.pdf2017-05-04T12:29:31.000Z"b04da5a21b35e25472cacecd53159ce5"283792STANDARD109/guideline643.pdf2018-03-28T14:48:18.000Z"f6d8b71858a2859cff21b5d0613c9608"259607STANDARD109/guideline644.pdf2017-02-10T12:03:38.000Z"f2f9e7e199426aadfde3836ae37401fc"140548STANDARD109/guideline645.pdf2017-04-27T12:50:48.000Z"ba5e7806d35e759c90ccc1f28081bd43"91512STANDARD109/guideline646fm.pdf2017-05-03T11:17:15.000Z"3c42e2ac04b5f22f7c8845acc0eab008"427292STANDARD109/guideline649.pdf2019-01-11T11:24:55.000Z"fd3a8dff48a070b9f1896fea510fed89"116718STANDARD109/guideline656fm.pdf2018-12-11T16:35:46.000Z"8bf19aea39a636a03858c3d7b708fe5a"170459STANDARD109/guideline658.pdf2018-08-14T15:30:35.000Z"61be37b86327df3ddb734be161cda318"270755STANDARD109/guideline669.pdf2017-12-19T14:39:38.000Z"35a509d208138145f91caa0e39ac4f93"137967STANDARD109/guideline67.pdf2018-09-28T15:13:19.000Z"40cac839208be4bfa5d7961f98e29cf4"119150STANDARD109/guideline671.pdf2018-10-22T15:14:22.000Z"34815bad4a84dd89b65df937eef01382"760452STANDARD109/guideline675.pdf2017-04-04T11:02:55.000Z"feb36a1f4154edb7f3ba432af900cea5"219855STANDARD109/guideline676.pdf2018-09-25T13:03:20.000Z"a9049b941124e021e6398149bbbf5bd4"1713415STANDARD109/guideline677.pdf2018-08-20T15:45:41.000Z"511795d90a399c223a760e80f2347698"169612STANDARD109/guideline68.pdf2018-02-22T13:18:56.000Z"16cfc51c7faa4bda8befa5f83d4beee8"163129STANDARD109/guideline681.pdf2017-09-12T15:42:26.000Z"a356cda9609710fab64d47a2ca0244fe"229732STANDARD109/guideline683.pdf2019-04-23T15:46:00.000Z"8051ba6a479a1e50b9fd0e753252df78"20722STANDARD109/guideline684fm.pdf2018-04-30T13:12:28.000Z"a2ff9c01029f19e64a278f1c7ba30f89"152737STANDARD109/guideline687.pdf2018-04-03T13:45:26.000Z"f875cca7dad7acd2731704b97e197abd"281658STANDARD109/guideline688.pdf2018-09-28T15:56:16.000Z"69a74f3ddd01115e78c5d277d4b3ab11"108241STANDARD109/guideline69.pdf2019-01-25T11:08:56.000Z"a5a51c2362a144ad98428b9412c7ae75"461128STANDARD109/guideline690fm.pdf2018-03-21T09:53:57.000Z"3d5b7eb27314dd6564ceef24e9a1814f"139837STANDARD109/guideline693.pdf2018-02-02T15:52:57.000Z"b8fa19f75c70066375365bcbae80e3e9"551263STANDARD109/guideline697.pdf2019-01-28T14:42:00.000Z"7eaf4c3ac75321fc08a8c6da27039c11"142470STANDARD109/guideline698.pdf2018-10-12T15:24:49.000Z"685bfcc777ecf027d171292d4bd62875"142186STANDARD109/guideline699fm.pdf2018-01-02T17:06:26.000Z"0012d684cbe94d1a5cb968c42ed90986"267017STANDARD109/guideline70.pdf2019-04-15T14:49:44.000Z"9aef7cb0dd50bd9ef4b44c06b015d6df"185324STANDARD109/guideline701.pdf2019-03-14T14:08:40.000Z"5c25f27a76dee3eb530c183cf9bef515"241432STANDARD109/guideline703.pdf2018-09-10T15:13:48.000Z"4dca0cb96675ab988d126ec3b38bd4ca"211939STANDARD109/guideline704.pdf2018-10-12T15:26:31.000Z"9d0446c71417e33117967213ea5c6e63"227238STANDARD109/guideline705.pdf2018-07-30T11:11:18.000Z"56a3869d26bf9b949356c9a5976ee3e2"832537STANDARD109/guideline706.pdf2017-07-31T11:50:09.000Z"3bfeac4e8776c98bfdd3f78dcb4ab471"631553STANDARD109/guideline709.pdf2019-03-07T14:03:27.000Z"0156f7674766a6f24878c7559a154ae9"271001STANDARD109/guideline710.pdf2019-03-07T14:44:50.000Z"e3e7376d85b489b38dbfcce77bfa4d37"253400STANDARD109/guideline713.pdf2018-07-12T10:39:05.000Z"17710d0dc05d7503997400398ccd224a"474315STANDARD109/guideline717.pdf2019-05-01T08:28:26.000Z"a13aa059522e21b02c4b063e6fddf099"143751STANDARD109/guideline72.pdf2019-05-03T14:28:08.000Z"fe5dcd71a4de5e761e11a46f5dab6ac1"89304STANDARD109/guideline727.pdf2019-02-19T14:03:15.000Z"2279776ef30e0ddb90b29f29a648e417"244219STANDARD109/guideline729.pdf2017-01-27T15:31:37.000Z"34e3c3d1c2dbd1069ddc9af1b7b3dd2d"180921STANDARD109/guideline730.pdf2017-05-22T10:52:47.000Z"21f2545a71ab9614c77b8475c094ba01"45716STANDARD109/guideline736.pdf2017-08-02T11:34:21.000Z"ba07607d5b9f29f2f2d0c1d010b724cd"168962STANDARD109/guideline737fm.pdf2018-06-14T10:28:22.000Z"7c8f7bbd9c76d1a094091a41dc5d856f"206622STANDARD109/guideline740fm.pdf2018-03-19T17:00:19.000Z"c991d23efaa8752d749cfcbbcb004007"295353STANDARD109/guideline743.pdf2019-03-08T16:02:03.000Z"075db4914543236dfe928e02b09b92cc"101520STANDARD109/guideline745.pdf2018-02-19T15:27:06.000Z"d769a214fd9d28b114afdc31da6c1888"106939STANDARD109/guideline748.pdf2019-02-01T15:31:22.000Z"53af7565283c912896aa2f5784e248b1"102752STANDARD109/guideline749fm.pdf2018-03-20T17:08:56.000Z"624e6d82ea48e174f7b109bc2efc76a1"372550STANDARD109/guideline75.pdf2018-05-30T10:15:52.000Z"044102b9c46fdfb7f56fef5eee011d61"96892STANDARD109/guideline750.pdf2018-09-13T14:57:11.000Z"fe1dc61a12d624c0f8acf885d0282ffb"1066116STANDARD109/guideline751.pdf2018-09-07T11:04:17.000Z"3b14234cac28068c968817eb9b68bef0"83958STANDARD109/guideline752.pdf2017-05-02T08:59:53.000Z"88b9c5df291a0a5acf03662dd2c8ea7c"486452STANDARD109/guideline753.pdf2019-03-04T14:38:25.000Z"c25ec5e6bc44165ff0062822e4f90c55"477307STANDARD109/guideline753a.pdf2017-04-04T11:03:20.000Z"7dfc6d1ff753d98fb971a451cb79540f"734220STANDARD109/guideline755.pdf2019-04-05T15:30:47.000Z"915155fb2f1cde804f015d6db85c311d"2080014STANDARD109/guideline756.pdf2019-04-05T15:57:15.000Z"563a448e756be4174f467abafc9baf19"171449STANDARD109/guideline757.pdf2019-02-19T11:49:25.000Z"e18c4fa5997ce4a21cb85a92a44aaffa"490089STANDARD109/guideline760.pdf2019-02-27T11:06:10.000Z"710007931c1f61dccd7a69790e7adf14"504329STANDARD109/guideline761.pdf2018-01-17T10:43:07.000Z"3cf15bb2ae58e02ad18808aa31975527"730896STANDARD109/guideline763.pdf2019-04-05T09:04:24.000Z"59ede152a112bf67f1e995bdfadca6f5"98818STANDARD109/guideline764.pdf2018-01-17T11:20:20.000Z"aa747026c1a64bb0685355e10f10a457"773458STANDARD109/guideline765.pdf2018-01-17T11:12:54.000Z"439c489e831ba848f47cdcad051bd2cb"685151STANDARD109/guideline766.pdf2018-01-17T10:21:43.000Z"29eddedb0b8863fc18a3ceef5735c835"755577STANDARD109/guideline767.pdf2018-01-17T10:44:20.000Z"64e391236d1e4d971a9fb92deea2e497"801844STANDARD109/guideline768.pdf2018-01-17T09:19:25.000Z"89760132b8c994783e21fbb03a83a7f0"765485STANDARD109/guideline77.pdf2018-09-20T10:58:17.000Z"c29a8bedf94ddd49be1a97c61a26623b"146631STANDARD109/guideline770.pdf2018-04-10T15:15:26.000Z"5e809eff4796747dde12ab6d48ed9e32"198835STANDARD109/guideline771.pdf2017-08-31T13:39:08.000Z"94ef3fd5797ec72c57869c654e14a7c6"216054STANDARD109/guideline773.pdf2018-03-26T11:26:47.000Z"1e44c31fbd69b50ce08bc54011756374"1067008STANDARD109/guideline779.pdf2018-09-24T10:21:49.000Z"a509c33c2651712b1655f440aef18dea"85271STANDARD109/guideline78.pdf2018-09-20T12:25:40.000Z"74e70b1ca721ff64a6c6d6963e29838f"125020STANDARD109/guideline783fm.pdf2018-09-26T13:46:59.000Z"713c4881d0f374a8b7d96c9648e1d8af"539881STANDARD109/guideline79.pdf2018-09-07T07:53:58.000Z"feb3bf0de8249bc51710057f1ab4d412"316245STANDARD109/guideline792fm.pdf2018-03-21T09:54:24.000Z"4f2c2c34126fecb5e711085837dd8643"190561STANDARD109/guideline801.pdf2019-05-07T10:00:20.000Z"b98604dc9546656734c1de0a0b5dbd1a"508168STANDARD109/guideline804.pdf2017-05-26T09:04:09.000Z"9c7285bf983d1dc49858ce7a5232f22b"183158STANDARD109/guideline805.pdf2017-04-28T15:28:32.000Z"2d589e2a65600a14d72f68ae15d1f92b"285747STANDARD109/guideline809.pdf2018-09-07T07:58:52.000Z"3a51889b7e2c301bf06561b007cd68f5"310952STANDARD109/guideline810.pdf2017-04-28T15:26:57.000Z"d803bcaffd6c56e36daa32325a71dfa7"270625STANDARD109/guideline812.pdf2019-05-08T13:26:06.000Z"618c698545e2434c1bcd575d8bae7f52"25426STANDARD109/guideline814.pdf2017-04-28T11:34:04.000Z"327224ae4983aeb3fad277dfd7f89c00"548675STANDARD109/guideline815.pdf2019-03-27T08:29:21.000Z"c2da4ef395b9167b6a2be451ac921cc9"737721STANDARD109/guideline816.pdf2017-07-05T12:31:33.000Z"4d0b6d69b20f5fa0615d3b797ed2e705"360379STANDARD109/guideline82.pdf2018-10-12T15:25:35.000Z"d075a0e2d085bc9364ee5141de924f29"142503STANDARD109/guideline822.pdf2019-01-25T13:36:47.000Z"95199acf63400b10303d268feba665e1"178475STANDARD109/guideline823fm.pdf2017-05-03T09:31:20.000Z"2bd9c16fa30076e61260a278d6bf847d"1186299STANDARD109/guideline824.pdf2018-02-06T16:20:55.000Z"d96e8e8640556b7e380114709670e1d2"623196STANDARD109/guideline826.pdf2017-07-04T10:49:53.000Z"be3a155ff8e65096ccd2a3212e1efe81"285976STANDARD109/guideline827.pdf2017-08-29T15:03:01.000Z"bd6fb87225aed559fac6dc8aa3532197"332077STANDARD109/guideline829.pdf2017-06-21T12:40:41.000Z"91d48e530d6a729d8b52bfaf9197025f"123307STANDARD109/guideline830.pdf2017-08-31T14:01:39.000Z"da23079ed0c9157d641509cc81b05f2b"314615STANDARD109/guideline832.pdf2017-08-18T13:16:35.000Z"a5caeac29debdda3d2c336a286b08cf6"323920STANDARD109/guideline835.pdf2017-07-20T07:33:11.000Z"7531a18f42a57dcec3ddbe021cc768c6"770586STANDARD109/guideline838.pdf2018-03-28T14:01:36.000Z"22521083ce3a3eb11cb3b9c15a303085"198321STANDARD109/guideline84.pdf2018-02-13T11:57:58.000Z"92335a7f5fce28059b5046636751eace"430269STANDARD109/guideline840.pdf2017-11-17T16:08:33.000Z"cbd8ae0225eb00d7ba861b6de43560fb"754899STANDARD109/guideline842.pdf2017-11-13T12:21:23.000Z"429dafbdd1cbc740c1edabc58d083db9"506377STANDARD109/guideline854.pdf2019-04-16T11:10:54.000Z"9e2dea672769bac703caf6799fae1d62"118554STANDARD109/guideline857.pdf2019-04-15T15:03:43.000Z"e2fef193f8f238bbd747c5095dd28dde"223212STANDARD109/guideline858.pdf2019-04-15T15:03:58.000Z"ea06663bf2ba8e7330bb38e1cb976976"282046STANDARD109/guideline86.pdf2018-02-01T13:41:36.000Z"ddd65be6121735041eebc160e5057ea3"438334STANDARD109/guideline862.pdf2018-09-10T11:14:35.000Z"62fe7897e1d86902d19219ec1f7efbd0"372521STANDARD109/guideline863.pdf2018-07-19T13:10:36.000Z"35e3844f9d4ca2abb404de7da42b6cc9"250164STANDARD109/guideline864.pdf2019-04-05T15:23:58.000Z"3e33d7c12708846a02e3b798d604ec93"298351STANDARD109/guideline866.pdf2018-10-11T12:10:11.000Z"467e565ae748a26440f6fda74d2632b8"937546STANDARD109/guideline867.pdf2018-10-25T13:42:57.000Z"98a822b4d4ee9d02a3f8585620740a75"505456STANDARD109/guideline87.pdf2017-01-27T16:27:19.000Z"f125d0999884376fc9296d79ea7dbdd3"168233STANDARD109/guideline870.pdf2018-10-11T12:10:25.000Z"d5f21fb1bf86f58326b6c77c7fa7e620"401062STANDARD109/guideline88.pdf2017-07-10T09:03:50.000Z"23fe89cee29494d31dae833b8acf351f"840123STANDARD109/guideline89.pdf2018-02-16T11:50:54.000Z"3e329f80316404a480a3b6d517a5b690"296750STANDARD109/guideline93.pdf2018-10-22T13:04:44.000Z"22b85733f8e3b482f8508e21a648138f"127195STANDARD109/guideline98.pdf2018-02-27T16:34:59.000Z"53a79b866acd8c8ae452623585b41e39"161927STANDARD109/guideline99.pdf2017-03-22T09:51:03.000Z"86c20894e0320c85e53de7574c0f32b2"175357STANDARD109/matsop11.2.pdf2019-03-13T10:08:02.000Z"3a361c53451a2d3c0dfbb507c0fa869e"552218STANDARD109/matsop15accesstohealthrecordsdraftfinal260917.pdf2018-02-09T16:10:55.000Z"bbc9ff63e8ad305a3744d750a9c1f53e"113595STANDARD109/matsop3.2.pdf2019-03-26T10:16:25.000Z"71512422cd21b522e56afda97dd04590"735240STANDARD109/policyforcommercialcollectionofumbilicalcordbloodforstemcellcollectionbhtpol189finaldec2017.pdf2018-02-09T16:18:26.000Z"1bd7f2ae4320b88420d1c1cc88a9c18c"252379STANDARD109/safeuseofnitrousoxideandoxygenmatsop10.pdf2018-02-09T16:12:21.000Z"47fe121b01e94ab315cd6919c9425c65"123898STANDARD109/stepbystepguideforgentamicin.pdf2019-03-13T12:51:18.000Z"8b4245b7110a8f7b724b405c1d0e6a4c"771121STANDARD109/stepbystepguideforteicoplanin.pdf2019-03-13T12:51:29.000Z"1a2fd725157af97c1daf44d6266da069"835653STANDARD109/stepbystepguideforvancomycin.pdf2019-03-13T12:51:39.000Z"29f234caa0feafe17ea34ad6dde3ec7d"895434STANDARD109/wzz1992sepsisadultinpatients6june2018.pdf2019-02-28T11:40:29.000Z"2a5fcfd2b289b10d70edafae42067f33"1607950STANDARD11/multipledailydosegentamicinmonitoringchartreviewdatemay2020.pdf2018-06-25T07:47:38.000Z"5e9cb632b5d2b6973c593e8756154edc"151202STANDARD11/oncedailygentamicinmonitoringchartreviewdatemay2020.pdf2018-06-25T07:47:23.000Z"b62159f6889d654fcb21a3540daadd39"150411STANDARD11/utiinchildrenalgorithm.pdf2018-03-09T09:41:39.000Z"81a017fcd90ce955135abeb2f2b48ae3"172261STANDARD11/vancomycinmonitoringchartreviewdatemay2020.pdf2018-06-25T07:48:05.000Z"d7f1b74e82ad0edf6bcec123542a732b"150969STANDARD11/womenunder65withnoriskfactorsforresistancealgorithm.pdf2018-03-09T09:41:09.000Z"2d733e86347a9e7c1944dc9d8ac931ee"124490STANDARD118/CrClcalculation.png2016-11-27T12:58:53.000Z"72cd3140a998471d6fee4ec779dbc19f"3307STANDARD118/GentamicinBDmonitoring.docx2016-11-27T12:58:53.000Z"d573f33c93c108ec14180607f42ee166"20540STANDARD118/GentamicinODmonitoring.docx2016-11-27T12:58:53.000Z"78a946f8698be202647275fb9d802108"26035STANDARD118/SWFTAntibioticDiabeticFootGuidelines.pdf2016-11-27T12:58:54.000Z"6e740f84f6ab4bbbfc15011e4e4a8e5b"80510STANDARD118/SWFTpenallergyposterApril2015withASGcomments.doc2016-11-27T12:58:54.000Z"4ee35aefdb91d74d4d3ebbf64efb7246"216576STANDARD118/SepsisorSevereSepsisManagementSWFT.pdf2016-11-27T12:58:53.000Z"93490a4630fa1e6db6d45ddd96978083"293096STANDARD118/SepsisscreeningtoolSWFT.doc2016-11-27T12:58:53.000Z"a5966f8c7633ad837110d6d85b6387f6"226816STANDARD118/Vancomycinuseandmonitoringv1September2015.docx2016-11-27T12:58:54.000Z"962490613c20c1249d3e7f7b2a892441"23874STANDARD118/VesselHealthRightLineRightTimeDecisionTool.pdf2016-11-27T12:58:54.000Z"5aae2dffe9eb6115a4dc7ff911280c66"163472STANDARD118/ivtoposwitchguidelinesforantibioticsfinal.pdf2017-11-13T08:48:44.000Z"54a655a9cffed47c2ad06fc0309cf343"260926STANDARD118/penicillinallergytrafficlightposterfinal.doc2016-12-20T08:53:59.000Z"6d844a8dc21c38489c676be935941c22"223744STANDARD119/AntibioticMan.docx2016-11-27T12:58:56.000Z"f96186199d71075bffc58225ec9d5d89"1192903STANDARD12/BehaviourChangeforAntibioticPrescribingFINAL.pdf2016-11-27T12:58:57.000Z"a5b2fae8265fdc981ad2830101b0b06a"953316STANDARD12/bapenulna.jpg2017-07-27T16:00:58.000Z"215674fc6f8d0124ded3ab6635982287"100319STANDARD12/carepathwayforutidiagnosisintheelderlyoct2018v4.png2018-10-12T09:18:25.000Z"aa3d7d187133336070bba093f64a0f51"105054STANDARD12/carepathwayforutidiagnosisinyoungermenoct2018v1.png2018-10-12T09:23:11.000Z"bb09a9e3ab0bf057de025e76fe152d97"80352STANDARD12/carepathwayforutidiagnosisinyoungernonpreganantwomenoct2018v1.png2018-10-12T09:23:26.000Z"1eaefa4dd97cc575c253357beef5e688"81958STANDARD12/ifihaematologyguidelinefinalaugust2015.may2017ammendment.doc.pdf2017-05-04T08:27:44.000Z"f23ff4a54ed4c942b2f330307456e6a8"137679STANDARD12/ifiituguidelinefinalaug2015.may2017ammendments.pdf2017-05-04T08:27:25.000Z"5ec7e815be7980be3d85ca464436a73a"143182STANDARD12/influenzaflowdiagramjan2019.png2019-01-23T16:11:07.000Z"5ea7898dbc36f79aa464b81848292394"64250STANDARD12/influenzaprophylaxisphe2018.2019.png2019-01-16T09:35:59.000Z"813738b16761f761824e7b3e41bff6bd"115686STANDARD12/influenzaprophylaxistableoct2018.png2018-10-19T15:18:11.000Z"aa718c7451a15f9c409f183dbc23b00b"50569STANDARD12/influenzarenaldosingoct2018.png2018-10-19T08:03:40.000Z"ae4b650b68c6f17c49bfc9a08b9ae643"64913STANDARD12/influenzatreatmenttableoct2018.png2018-10-19T15:18:01.000Z"d5664f9a3a5d444ce2ffde2147813544"44607STANDARD12/ivzanamivir1.jpg2019-01-15T15:06:21.000Z"4a458372948d2d17aa4c8f9f4b5b9224"93164STANDARD12/ivzanamivirrenal.jpg2019-01-15T17:05:00.000Z"d2efb2a7c293fa9d7d47d51ba5408e1e"86962STANDARD12/neutropenicsepsisexp2019.pdf2017-10-18T16:28:02.000Z"932d83eb6a1e6dec37d7bec647bcfd1d"388590STANDARD12/spleenpreventionandtreatmentofinfectioninpatientswithabsentordysfunctionalspleenfeb2019.pdf2019-02-20T14:02:24.000Z"ef45fc14dba1b0c05d818f197ae3430e"78365STANDARD12/utialgorithmpregnancy.png2018-02-19T16:23:42.000Z"0f7648e5191f584873f4ca6e8323de73"44023STANDARD12/vancomycinciprotocolmay2017.pdf2017-06-22T14:56:15.000Z"15780a63120f359c5f7bc4120aeeb744"120637STANDARD123/NUHlogo.png2017-08-08T11:20:03.000Z"2bd8b0306cca6352e53423fc6fd1764e"20654STANDARD123/cuhnhslogorgb.png2017-08-08T10:57:06.000Z"67792ea005ca63addb73a5328eecec35"77620STANDARD14/2014reviewGentamicinTDMFINALv31.pdf2016-11-27T12:59:01.000Z"aa8b92d57b1764d89c81fb22eaae49e3"211918STANDARD14/2014reviewGentamicinTDMFINALv32.doc2016-11-27T12:59:01.000Z"8d0eabe98101f4cf1855350d5deea9e8"406528STANDARD14/2014reviewGentamicinTDMFINALv32.pdf2016-11-27T12:59:01.000Z"c1f750258489f1674aaaa887b21aaae7"211754STANDARD14/2014reviewVancomycinTDMFINALv31.pdf2016-11-27T12:59:01.000Z"4bdbc2d5edd0bf65940907bc3d847f03"216419STANDARD14/2014reviewVancomycinTDMFINALv32.doc2016-11-27T12:59:01.000Z"5535e2f739c197b21649fb8af7f4329a"318464STANDARD14/2014reviewVancomycinTDMFINALv32.pdf2016-11-27T12:59:02.000Z"8a3a9dac489972be2e1ab4e74a3f2ad9"217134STANDARD14/Feb2015reviewoncedailygent.pdf2016-11-27T12:59:02.000Z"aa871880266e71cad998361b2721505e"211330STANDARD14/Feb2016reviewoncedailygent.pdf2016-11-27T12:59:02.000Z"e124fd7c2cdda9baca873cd4cb08f17f"211330STANDARD14/Gentteic2016v1.pdf2016-11-27T12:59:03.000Z"b4d6910e80cd310580538d88fd86b931"102611STANDARD14/HDUHBAllergyPoster2Jan2016.pdf2016-11-27T12:59:04.000Z"ad414f9cb9aa5f85517bbbd8de50b2e4"64277STANDARD14/Lymphoedmanetworkcellulitispathwayvers301092015.pdf2016-11-27T12:59:04.000Z"c47c450aa8d6aa8cdc27d9bb2baf1fd6"292049STANDARD14/MultipledailygentMarch2016NP2.pdf2016-11-27T12:59:05.000Z"f72192ff658d9cb6f5d28965fc55b89b"206727STANDARD14/Multipledailygentfeb2016NP.pdf2016-11-27T12:59:05.000Z"f0345bd89914a804bf1247e2834148b7"212474STANDARD14/TEICOPLANINGuidelineMarch201604.pdf2016-11-27T12:59:05.000Z"a5c0011c0e001d07428dda1e49f3e0fa"147704STANDARD14/TEICOPLANINGuidelineMarch201606.doc2016-11-27T12:59:05.000Z"94ff6160da67db5310b6c1348fa484ba"79872STANDARD14/TEICOPLANINGuidelineMarch201607.doc2016-11-27T12:59:05.000Z"b0b9cae8846fba4c143f31f6fea6ec11"182784STANDARD14/TEICOPLANINGuidelineMarch201607.pdf2016-11-27T12:59:06.000Z"60386bec9d9803b1019ccd27e7dad3c2"166662STANDARD14/TEICOPLANINGuidelineMarch201608.1.pdf2016-11-27T12:59:06.000Z"f613220ac59b3da115502b4674bc3d0a"146893STANDARD14/TEICOPLANINGuidelineMarch201608.pdf2016-11-27T12:59:06.000Z"9e7712c56efed9c47c4a6bd1d10f4b4a"147526STANDARD14/VancomycinreviewFeb2016.pdf2016-11-27T12:59:06.000Z"1a772ccfc6ea527ec079832352546807"217162STANDARD14/antimicrobialdosinginextremesofbodyweight.pdf2018-11-06T16:40:05.000Z"ea1085ca2e692e29f06c8e8b937a081c"460677STANDARD14/antimicrobialprescribinginrenalimpairmentinadults.pdf2018-11-06T16:39:54.000Z"7b870b13c84418765033a259f5361552"261244STANDARD14/cid1390oseltamivirtamifluandzanamivirrelenzadosingrecommendationsforadultswithrenalimpairmentnovember2017.pdf2018-09-13T13:50:51.000Z"f34e5c6dc0465d0cd669331a30a0a47d"553269STANDARD14/english.pdf2017-03-17T10:13:21.000Z"877a70ce1f2320b1cabb143d7c3b0ee1"24126STANDARD14/english1.pdf2017-03-17T10:19:14.000Z"dce5c756c441e9eab823f921fd12667a"29240STANDARD14/gptreatingyourinfectionleafletv412.11.15bilingual.pdf2018-03-23T11:53:36.000Z"333470942569dfd9783b81c04346c014"503337STANDARD14/gptreatingyourinfectionleafletv4221018welshbilingualfinal002002.doc2018-12-05T09:10:26.000Z"fedfa9dd41fe98b604785c63abf7e791"644096STANDARD14/gptreatingyourinfectionleafletv4221018welshbilingualfinal0020022.doc2018-12-05T10:14:25.000Z"de11f5a086702daa997c9e3c70c850a9"644096STANDARD14/guidelinessplenectomynhsleafletlinkmay201709.pdf2018-04-09T13:55:45.000Z"b97a0460e967d01086d4362eae3198d5"223840STANDARD14/malariaguideline2016.pdf2017-11-07T16:01:32.000Z"90972e9ada74b704ef56b2e967be105b"450916STANDARD14/multipledailygentmarch2016np2.2.pdf2016-12-30T16:06:38.000Z"38eb614562b476ba0d0f96d5c1f966b9"208043STANDARD14/myienglish.pdf2018-04-10T10:27:39.000Z"04a67797925a09b0d27170a8839f03a1"1461419STANDARD14/myiwelsh.pdf2018-04-10T10:19:09.000Z"8e1a4f21c4c3e9a7cf3bf1c6877671e6"1201105STANDARD14/neutsepsisguideline.pdf2018-09-13T13:38:30.000Z"3b1dc95ff4a80fe39ad24ea910c25e38"557501STANDARD14/pdfcoamoxform.pdf2019-05-20T14:17:40.000Z"a24767fd5f80178c8036c722ba2e9912"366558STANDARD14/pdfmeroform.pdf2019-05-20T14:17:32.000Z"23bbc92ff74a40b9752007f20184ed2c"365020STANDARD14/pictorialmanagingyourinfectionleafletv2.pdf2018-11-29T15:23:12.000Z"4c34d808e57fad4e60562d7f0ce66f1d"1344207STANDARD14/pictorialmanagingyourinfectionv2welsh.pdf2018-11-29T15:25:16.000Z"d72986dd056cddafd18f0da46b3a0d9e"1328678STANDARD14/postampmeetinggentamicinmonitoringsheet.pdf2019-05-20T13:50:01.000Z"97509f3773c9a05e80b9a66349dc9e70"181214STANDARD14/ppicdiffinfectionletter.pdf2018-05-10T09:12:05.000Z"6e852e977a95259e2ce2d30d53cef134"419327STANDARD14/rationaleforcoamoxiclavform.docx2019-05-20T14:13:25.000Z"149e5821be85c49182e779188c56d8ac"18868STANDARD14/rationaleformeropenemform.pdf2018-11-13T16:11:30.000Z"23bbc92ff74a40b9752007f20184ed2c"365020STANDARD14/rationaleformeropenemformv2.docx2019-05-20T10:00:44.000Z"cf70dfb88a37a660504f07c8adb88607"19340STANDARD14/renalimpairmentdosingforoseltamivirtamifluandzanamivirrelenzainadultsnovember2018.pdf2019-01-31T16:21:48.000Z"58125761b3524b63cd19284b6004f4eb"587618STANDARD14/splenectomyguidelinesfinalmarch2018.pdf2018-05-10T10:19:03.000Z"541588c585b6165a4ce331523dac21a0"243649STANDARD14/targetutileafletforolderadultsv11.doc2018-10-31T11:51:32.000Z"c1ca425a7a9e7179e950a068a4940d42"707584STANDARD14/tyibilingual.pdf2018-04-10T10:22:54.000Z"25508a31c2650cdcb376bab562f043dc"456239STANDARD14/tyiutileafletforolderadultsv11welsh.pdf2018-10-31T11:51:44.000Z"8df4c61a789794fbdfda11f83cac454f"360035STANDARD14/utienglish.pdf2018-04-10T10:23:07.000Z"d5993e1b1f455d6735354eb02cdf787b"296084STANDARD14/utitreatmentinadults.pdf2018-10-31T16:44:51.000Z"c8ffa4e488f20732d3a54e5b524df5eb"241553STANDARD14/utiwelsh.pdf2018-04-10T10:23:21.000Z"0231d962ad07e55882193ddc3d1a7536"327640STANDARD14/welsh.pdf2017-03-17T10:16:22.000Z"caf46687921dd1bd528ebc3cae8fc4fc"107126STANDARD14/welsh2.pdf2017-03-17T10:19:06.000Z"a6554ba3eba0794b6c44dcd7e6832f08"108521STANDARD14/whatsnewdecember2018.docx2018-11-29T16:33:11.000Z"dd65a580731f873d8117cc340ca92256"1082768STANDARD14/whatsnewseptember2018.docx2018-11-29T16:11:53.000Z"77f8b065f4a8b1cef7d70252e6ee5c17"13601STANDARD16/AntimicrobialprescribingpolicySept14final.pdf2016-11-27T12:59:13.000Z"93e741c1382a8798927e02727e57a9bb"1175703STANDARD16/CFIVantibioticdosingandadmin2014FinalupdatedNov2014.doc2016-11-27T12:59:14.000Z"fe3a76051e205a562a2c6e15f0326254"119808STANDARD16/CFIVantibioticdosingandadmin2014FinalupdatedNov2014.pdf2016-11-27T12:59:14.000Z"b243ea335e2b268371b234faffb22bcb"201520STANDARD16/CFIVantibioticdosingandadmin2014FinalupdatedNov20143.pdf2016-11-27T12:59:14.000Z"f815937c5c6923f382b1f4275352c5c0"161240STANDARD16/EndoscopyGuideline.pdf2016-11-27T12:59:14.000Z"ca2e32a561656dd2a67716cc578a7429"69342STANDARD16/InfluenzaTreatmentGuidelines.pdf2016-11-27T12:59:15.000Z"db7e03643dc9440ecf72e3eee49b6b13"96964STANDARD16/MaintenancedosesforVancomycin.pdf2016-11-27T12:59:16.000Z"52d552be5f980cbe71ad90d166729ac2"95408STANDARD16/MaxFaxandENTJointGuidelinesPostAGCJun15.pdf2016-11-27T12:59:16.000Z"16ff79afe67b84437613f3248ab4cb08"341755STANDARD16/MaxFaxandENTJointGuidelinesminorupdatedec2014.pdf2016-11-27T12:59:16.000Z"d64cb3b44186fdc79eb23ebecfa0b3fe"423801STANDARD16/MaxillofacialGuideline.pdf2016-11-27T12:59:16.000Z"40d9a490ed80391cc211d0dfebba6c28"122585STANDARD16/NUHCFMRSAdec2015.pdf2016-11-27T12:59:17.000Z"8ee43011219c0470b7816209430d01da"126668STANDARD16/NUHRestrictedList.pdf2016-11-27T12:59:17.000Z"e0b360711765abc23ab5ce7e5e9fb95d"131131STANDARD16/ObsGuidelinesOct2014.pdf2016-11-27T12:59:17.000Z"46aa1bdcc590771bff2752bd9bd794db"282094STANDARD16/RENALABApril2015postDTCfinal.pdf2016-11-27T12:59:17.000Z"2f65a244406c080c4663ceb3a8522818"309523STANDARD16/RestrictedListJanuary2016.pdf2016-11-27T12:59:18.000Z"47ae34504cfc890bc185e96c2d70b27f"169202STANDARD16/RestrictedListJanuary2016v2.pdf2016-11-27T12:59:18.000Z"17b1aa5d264edd0264e5ba5df6dd9fc5"169071STANDARD16/RestrictedListJuly2015.pdf2016-11-27T12:59:18.000Z"1ce013fa6f3ec0a762a627b4b416aa31"131267STANDARD16/RestrictedListMay2016.pdf2016-11-27T12:59:18.000Z"ba1cdedcf7bf305a86fb7f75f6aab1c0"170408STANDARD16/RestrictedListSept2016.pdf2016-11-27T12:59:19.000Z"34bec5321196071b9009794a866e0f5a"170990STANDARD16/RestrictedlistOct2014version2PDF.pdf2016-11-27T12:59:18.000Z"dfef18289d65a03e3d46fc861d7888e0"169558STANDARD16/TableofActivity2011.pdf2016-11-27T12:59:19.000Z"982ae2de73f5401c6b06fdbecdb0af6c"33499STANDARD16/Treatmentofinfluenzainadultsfinal2015.pdf2016-11-27T12:59:19.000Z"3d33441fccf9f763e0c572044d4a20f4"234417STANDARD16/UTIdiagnosisguide2015.jpg2016-11-27T12:59:20.000Z"3dfa96edb013b8afc2cb1dd547c550de"128132STANDARD16/UTIreferenceguide.JPG2016-11-27T12:59:20.000Z"e669bd9d3e10776faf8fc31eb4fd9932"115188STANDARD16/catheter.jpg2019-04-15T15:04:12.000Z"4257f67325060562055702a1b993586a"72389STANDARD16/fosfomycinguidelineNov20143.pdf2016-11-27T12:59:15.000Z"46ce8f33344a6d1d9d61b4a6bc4f7baf"185145STANDARD16/fungalinfection.png2018-08-16T08:15:59.000Z"121d2b953ee86f9f4af4a09c51dcbae8"27167STANDARD16/fungalinfections.jpg2018-08-15T08:58:32.000Z"7ca7b3f52dd2952edd34471e8995489d"87568STANDARD16/influenzaTreatmentguidelines2014final.doc2016-11-27T12:59:15.000Z"c2dec1c1d306d2def98c47de0f5a15eb"130048STANDARD16/influenzaTreatmentguidelines2014final.pdf2016-11-27T12:59:15.000Z"cdcdcb9a9025bf3d00b4a9a4bf09d69c"221999STANDARD16/mergedrestrictedlistOct2014version2.doc2016-11-27T12:59:16.000Z"cc533bcdb41da1d2616ce485e7629ab2"132608STANDARD16/nuhlrtibronchitisguidelineaugust2016final.pdf2017-01-20T12:14:49.000Z"bcc0b236541e3a6c4c5bfb9b0b1fb7a7"481815STANDARD16/over65.jpg2019-04-15T15:04:02.000Z"1fa8e0c35c8ff03052d289ac275efe26"198795STANDARD16/over65diagnosisuti.png2017-07-25T13:37:11.000Z"599e160eafd616b81825e3a7a6b92c53"86136STANDARD16/restrictedlist.pdf2017-12-06T15:14:18.000Z"718be137a386ff59c767f1c0e8662910"130523STANDARD16/restrictedlistapril2017.pdf2017-05-04T16:11:54.000Z"80d4ad1a9ee2076404991891f46b2998"172274STANDARD16/strokewardsrestrictedpolicydec2013.pdf2016-11-27T12:59:19.000Z"8bb9ddf8a99c732644ce1af72523207d"93255STANDARD16/strokewardsrestrictedpolicyfinaldec2015.pdf2016-11-27T12:59:19.000Z"d92eef51953de4bc653739d66a345f40"232864STANDARD16/tetanusclean.png2019-04-30T14:05:52.000Z"264ab81719ba5ed03cc69355ed718358"58561STANDARD16/tetanusprone.png2019-04-30T14:06:05.000Z"09a37649c92583b9ccd92b52bcc73342"38812STANDARD16/tetanuspronewounds.png2019-04-30T14:05:59.000Z"458850ca1fd5ecfde9dd0d9481e79570"76799STANDARD16/treatmentofinfluenzainadultsdec2017postdtcfinal.pdf2017-12-14T16:56:35.000Z"f8e8af8550c7051ab850e5a8ad7b9cd7"342430STANDARD16/tss.png2016-11-27T12:59:20.000Z"269889f61274010cd437de45d4cad057"54621STANDARD16/under65.jpg2019-04-15T15:03:52.000Z"db7490901ccc3cde22d72041a260a642"169793STANDARD16/under65diagnosisuti.png2017-07-25T13:36:49.000Z"93f908ec171a483b0007003ce2b9f5f8"60422STANDARD16/utielderly.png2019-04-09T11:44:02.000Z"75d3e156ce3d0eac98549f8b25d3dd75"65782STANDARD16/utiguide.jpg2017-05-25T13:22:52.000Z"3dfa96edb013b8afc2cb1dd547c550de"128132STANDARD16/utiguideline.docx2017-05-25T13:20:12.000Z"0dc9e0a4c2e3526225da9374c57aa50a"145706STANDARD16/utiyounger.png2019-04-09T11:44:15.000Z"4446265e718ced05e1f75ce7903c6b25"60838STANDARD16/vanc500mg.jpg2018-11-09T09:59:41.000Z"af8827dac2d8be13f38cb0ea2b321f88"45228STANDARD16/vancsticker.jpg2018-10-16T10:46:59.000Z"1ba55d851e06101a75811bcbb7040678"93963STANDARD17/AntimicrobialDosinginRenalImpairmentandCVVH.pdf2016-11-27T12:59:31.000Z"166ea64d98804bf2f2cba25a83ad9fbc"448937STANDARD17/HartfordNormogram.jpg2016-11-27T12:59:31.000Z"a23d70390350579b6297077eacd51395"16883STANDARD17/IVOSDec14.pdf2016-11-27T12:59:31.000Z"83778370524b1222ab3205d1a47e3803"78941STANDARD17/PHEabx3v2.png2016-11-27T12:59:32.000Z"29d723f8846a4675b1a2691c2a772d0e"137372STANDARD17/PenicillinPoster2016.pdf2016-11-27T12:59:31.000Z"6c54f502c5a4a477ab26852afcb46ea0"61674STANDARD17/UHLAntimicrobialPrescribingPolicy.pdf2016-11-27T12:59:32.000Z"dcfd79089cc9b9465dd2e099cd3eb43c"143888STANDARD17/UHLRedcib.png2016-11-27T12:59:32.000Z"58b3098347e04cce169d1ed27732cd26"10163STANDARD17/adultantibioticguidelinesforintravenouslineinfections05.13.pdf2016-12-30T15:27:02.000Z"1ccd39bc01a661f684b32ee89a833783"69161STANDARD17/adultantibioticguidelinesforpatientswithcirrhosis.pdf2018-08-10T14:33:09.000Z"fba8d53917f7fb678d7b6601ebba71bc"150777STANDARD17/adultantibioticprophylaxisguidelineforsurgicalandinterventionalprocedure.pdf2018-08-10T14:27:10.000Z"8ffe7a6885519d7168fd80b96ef6ebe8"119762STANDARD17/adultantimicrobialguidelinefortheempiricaltreatmentofpneumonia.pdf2016-12-30T13:20:50.000Z"b4703d6bbba47c5c84b49cd65bfb2c06"65378STANDARD17/adultantimicrobialguidelinesforempiricalmanagementofdiabeticfootinfections.pdf2019-03-13T15:21:49.000Z"0537afaba1ccf4073878a9dfb52ddc90"145766STANDARD17/adultintermittentvancomycinprescriptionchart.pdf2016-12-28T10:46:20.000Z"62c30ba90b78f3d20fb761722306b2ac"397119STANDARD17/adultlowerrespiratorytractinfectionsandcommunityacquiredpneumoniaantibioticguidelinealgorithm.pdf2018-08-10T11:47:03.000Z"41eb273f552b2926fe421d53b1758eae"77936STANDARD17/adultprimarycarecellulitiscarepathway.pdf2018-08-10T14:34:54.000Z"1b8f127022ae814d1af32b96e5e87eb5"2323819STANDARD17/adulturinarytractinfectionutitreatmentguidelinesandutiurinedipstickalgorithm.pdf2017-05-18T14:30:24.000Z"3cb31ec74da5e03e5e8df860be574b87"82140STANDARD17/antibioticpolicyandguidanceforprimarycarelmsgmay2017.pdf2017-05-22T13:13:21.000Z"d170e08d3727d7d1094adb218f4319be"787679STANDARD17/antifungalguidelinesfornonhaemoncpts.pdf2018-08-14T10:32:13.000Z"c8f5bd5184647e74cfd79e81ab96e5d8"378125STANDARD17/antifungalhaem.pdf2016-12-30T12:40:43.000Z"b13f7b6bbc108a71a51bb24b8af3604d"307080STANDARD17/antimalarialprophlaxisinrenaltransplantuhlrenaltransplantguideline.pdf2018-11-22T14:44:29.000Z"689cce88ba1d5c079f58c73f6f4d8676"52165STANDARD17/antimicrobialguidanceforkidneypatientswithspecificinfections.pdf2017-05-18T14:36:49.000Z"94948df8ce86d6cb7f45b8e10fd7dd69"46808STANDARD17/audiologyreferralforhighgentamicinlevelsuhlneonatalguideline.pdf2016-12-28T12:07:12.000Z"f4cb01b13733d126253b7a0c531187d2"38454STANDARD17/bkpolyomavirusinterstitialnephritisinrenaltransplantuhlrenaltransplantguideline.pdf2018-11-20T09:51:39.000Z"2fcc7a9a78e154bb3c793f434b9938b9"68543STANDARD17/cardiac.pdf2018-08-14T08:40:10.000Z"afd8e1af92b56007664b7bb3de180d0b"73134STANDARD17/cardiacsurgicalguidelines.pdf2018-11-09T16:08:01.000Z"afd8e1af92b56007664b7bb3de180d0b"73134STANDARD17/cdi.pdf2018-04-05T09:42:23.000Z"1c9cf71b2c5dcde1f4777f6f7efabda0"132264STANDARD17/chantibioticcribcardjun2017rrdhsbwithoutlinesepsisv3.pdf2018-02-16T08:22:41.000Z"5b5e273d7cd8a7bf207034abe42617b3"126854STANDARD17/childrenfebrileneutropaenia.pdf2016-12-28T11:40:22.000Z"388b70a87be0e6f690d8ef8b2ee81eb0"997684STANDARD17/childrenschildrensguidelineforthetreatmentofconfirmedorsuspectedcdinfection.pdf2016-12-28T11:44:34.000Z"6e3522af1c5d0511073687a7bcb4a75e"60527STANDARD17/childrenstyphoidguideline.pdf2016-12-28T11:46:23.000Z"8edf4298767acd6c9bc5064e5347d3e6"135061STANDARD17/colomycinpil.pdf2016-12-30T13:38:14.000Z"43bd13f01e3d228243579fec88d0253b"38800STANDARD17/criticalcareantimicrobialsummaryguidelines.pdf2018-08-10T14:51:43.000Z"0083d464403ffd0843a58cfef9ce63c9"82755STANDARD17/criticalcareoutreachantimicrobialguidelinesummary.pdf2018-11-07T15:19:11.000Z"20af28f5bdbafd50c958e90d24c58003"47733STANDARD17/cysticfibrosisemergenciesuhlchildrensmedicalguidelines.pdf2018-11-07T16:16:40.000Z"018e9933e949a8a27a0ea25327f4badc"368363STANDARD17/cysticfibrosisinpatientchestexacerbationuhlchildrensmedicalguideline.pdf2018-11-07T16:16:53.000Z"0f4ee0edeb65a6203687a4c2d6ccbc7d"2574870STANDARD17/cysticfibrosisoutpatientcareuhlchildrensmedicalguideline.pdf2018-11-07T16:16:57.000Z"2e044cfc096578b147fefe99f7a66b71"92696STANDARD17/cysticfibrosispaediatricprescribinguhlchildrensmedicalguideline.pdf2018-11-07T16:16:18.000Z"5e5c7feb5de8bef476db6e23d7922d89"145419STANDARD17/cytomegaloviruscmvinfectioninrenaltransplantuhlrenaltransplantguideline.pdf2018-11-22T14:30:20.000Z"e8035a8ec41881ca41ec3029ccbaf203"111504STANDARD17/diabeticfootreferraluhldiabetesguideline.pdf2019-03-13T15:28:52.000Z"b5a01f5042008b84b670ba901a9234b1"126023STANDARD17/dosemeguideforoncalldoctors.pdf2018-08-17T15:01:22.000Z"14f52c2cecd99d6473ad8edd9bac5112"375988STANDARD17/dosemeqasforvascular.pdf2018-08-17T15:01:18.000Z"6e7bfe1bbf445003b99e1dafe6b15256"492111STANDARD17/empyemauhlchildrensmedicalguideline.pdf2017-07-14T10:37:51.000Z"c24ae6cf2022a5598d0a2e60882a66b3"344362STANDARD17/encephalitisuhlchildrensmedicalguideline.pdf2017-07-14T10:29:02.000Z"a41d46a6b7cd03e333723244c2b725e8"87800STANDARD17/endocarditis.pdf2017-05-18T12:43:24.000Z"d261687f0fd2629e1c7fb7efdfdd6360"44165STANDARD17/entantibioticguidelines.pdf2016-12-28T12:53:19.000Z"b7c5d5d45ade364a4126deeddbd2b863"104358STANDARD17/feverinthereturningtravelleradultuhlguidelinemarch2019.pdf2019-03-13T16:17:30.000Z"03c142b45860426080c611038ca1b4a4"423878STANDARD17/finalopatsop2017.pdf2017-05-15T11:10:29.000Z"1d41a8ab1c5b8f304ef867352afed0f2"526188STANDARD17/genitalherpesinpregnancyuhlobstetricguideline.pdf2018-11-20T11:19:17.000Z"20f24a006220ecd0493eeb110adb8eb0"162244STANDARD17/gentamicinprescription.pdf2016-11-27T12:59:31.000Z"a842503b493ac4d7a084cac70b72418f"152252STANDARD17/groupbstreptococcusinpregnancyandthenewborn.pdf2018-04-18T11:03:41.000Z"cd2462920b3cee55ed5393b55704838b"158258STANDARD17/hartfordnomogram.doc2016-11-27T12:59:31.000Z"338bd7d051ef22fac28159e35a65958c"39424STANDARD17/hepatitisbvaccinationinchronickidneydiseaseuhlrenalguideline.pdf2018-11-20T10:23:05.000Z"4d068a33a033c4f1d60f70aa99de51f5"136784STANDARD17/hivinfectioninchildhooduhlchildrensmedicalguideline.pdf2017-07-14T10:31:12.000Z"2c42cfa8dee058dac552faad971a3631"82116STANDARD17/immunisationoftherenaltransplantpatientuhlrenaltransplantguideline.pdf2018-11-14T16:18:19.000Z"1a635876c6eb17f4c6ae98e553094579"42440STANDARD17/immunosuppressiontherapyfollowingkidneytransplantuhlrenaltransplantguideline.pdf2018-11-14T16:39:39.000Z"3c60c95ccc9cced7db4e8ca531cdabdc"57666STANDARD17/influenzafluuhlchildrenshospitalguideline1.pdf2018-02-16T15:01:29.000Z"e43bf785543d4ac274ec7dda98a8d473"567218STANDARD17/interpretingdosemereportsposter.pdf2018-08-17T15:01:08.000Z"77f031dafd7c3c2346414c733ce5253c"381119STANDARD17/intravenousvancomycinduringhaemodialysisuhlrenalguideline.pdf2018-11-14T15:14:10.000Z"69d24390ea7b71ad4bbdfe679aa4296e"40464STANDARD17/labourpyrexiaflow.jpg2018-04-30T09:20:53.000Z"69270b48959e98553302629043003bc7"73867STANDARD17/lupusnephritisuhlrenalguideline.pdf2018-11-09T13:07:50.000Z"b832d86cc2d2c34ca91be5628cc1e88a"114517STANDARD17/lymphoedema.pdf2017-05-18T08:36:13.000Z"7387e377ba913ebc54d872788340c77a"110991STANDARD17/malaria.pdf2017-05-15T14:00:24.000Z"183ccc8f01c8abb24a762f8819d422f6"105830STANDARD17/malariauhlchildrensmedicalguideline.pdf2017-07-14T10:18:30.000Z"d7185d77da731b2db6a04eebdc7288fa"192191STANDARD17/medicationallergiesuhlpolicy.pdf2017-04-07T09:15:19.000Z"d41fdc6a1782bfd51d6efdc5e382a4d8"131165STANDARD17/meningitisuhlchildrensmedicalguideline.pdf2017-07-14T10:23:52.000Z"fbaab5d1b715f5c096d71c9226e78c66"125158STANDARD17/msk14032016.pdf2017-05-18T09:12:01.000Z"2eb1ee3b84e91b125828638d8064fe38"233592STANDARD17/nebcont.pdf2016-12-30T13:38:39.000Z"050fda5dd4ca89d7402f80951907751c"30867STANDARD17/needlestickinjuriesuhlchildrenshospitalguideline.pdf2018-11-09T16:54:10.000Z"02d09fbe68b1b208a7a2213011a4118d"279211STANDARD17/neonatalherpessimplexuhlchildrensmedicalguideline.pdf2017-07-14T10:32:53.000Z"a88a1f2fe654e0e0516fe2446d659ff6"160604STANDARD17/neutropenia.pdf2016-12-30T12:43:56.000Z"b6c83eb0cd233f4a8af09a475f10318a"99227STANDARD17/nnuearlyandlateinfection.pdf2016-12-28T12:00:38.000Z"e28fed4cb59cf07068a6f345eb771179"206872STANDARD17/nnusurgicalprophylaxis.pdf2016-12-28T12:03:19.000Z"d20907ceddbd049de0b98b88fd47ab70"41044STANDARD17/nystatinmemo2016.pdf2016-12-29T12:10:54.000Z"0b0601768d9b464466c811c87aac1d8b"52769STANDARD17/obstetricsgentamicinprescriptionchartv42010.pdf2017-05-18T07:52:11.000Z"b8466b44c5dc0c891b5769a4644d68c6"61914STANDARD17/parenteralnutritionviaacentralvenouscatheteruhlpolicy.pdf2018-11-20T12:17:37.000Z"6aabf5a4c731517f033e0322c8e94c32"648977STANDARD17/pelvicinflammatorydisease.pdf2017-04-07T14:46:19.000Z"b4f9b6b4ffa3d155a985897d3849018b"70531STANDARD17/peritonealdialysisperitonitisuhlrenalguideline.pdf2018-11-22T15:14:28.000Z"00798b3c9c69f6774280d530cc8fcec6"58597STANDARD17/pneumoniauhlchildrensmedicalguideline.pdf2017-07-14T10:36:33.000Z"a7473fe503a25a81d27d145c331061ba"218080STANDARD17/policyforantimicrobialguidance.pdf2018-08-10T11:27:37.000Z"fdd842314b8bd4623dc0f6eaf477634c"231429STANDARD17/postcardiacsurgeryuhlchildrensintensivecareguideline.pdf2018-11-20T11:19:27.000Z"d6788c918fca36461220eb0968a771a3"1126932STANDARD17/preseptalandorbitalcellulitismanagement.pdf2017-05-15T14:47:29.000Z"7c0df170c9bac70438b975e4dee6403a"333525STANDARD17/preventionofinfectioninpatientswithabsentordysfunctionalspleenguidelines.pdf2018-12-17T15:34:52.000Z"bb25f86ae6323281aaf1ef8e743893dc"192062STANDARD17/primaryimmunodeficiencysuspecteduhlchildrensmedicalguideline.pdf2017-07-14T10:40:30.000Z"1f94cad82ab0ee53ce2b320a4928d91a"263340STANDARD17/prophylaxisduringchemotherapy.pdf2016-12-30T12:41:58.000Z"f10841b14155180c715c49fb2697711f"28585STANDARD17/pseudomonas.pdf2016-12-30T13:44:22.000Z"50e498c476d45e8e81f8fafca701d807"25336STANDARD17/pyrexiainlabourguidelineformanagement.pdf2018-06-19T09:52:08.000Z"54648847731956dd980d4ca712b6212d"282548STANDARD17/restrictedantimicrobials22dec2016.pdf2017-02-16T10:05:44.000Z"59ef4e412eea22c063fc066f7670252d"293716STANDARD17/sbar2antimicrobialavailability0317v2.pdf2017-03-29T07:32:33.000Z"6051a26dd9a517804ffa35c543b50f9b"223839STANDARD17/sepsisandsepticshockincludesuhlandketteringsepsispathwayuhlguideline.pdf2018-08-10T15:01:43.000Z"849c1b773aa04e0df11f1f9d3cb76ba4"420951STANDARD17/sepsisuhlchildrenshospitalguideline.pdf2017-07-14T10:21:39.000Z"00157cdc840253864850a34d2b8369e5"693332STANDARD17/septicarthritisuhlchildrensmedicalguideline.pdf2018-11-14T15:52:39.000Z"1029af56fb3aeb4330bce608af19d1fb"82839STANDARD17/sicklecelldiseaseacuteadmissionsuhlhaematologyguideline.pdf2018-11-09T15:35:38.000Z"d200b31b48dc6d0d16d0f994e386c47b"195887STANDARD17/sicklecelldiseasemanagementuhlchildrensmedicalguideline.pdf2018-11-09T14:52:46.000Z"73671a02da4b3cc99d8eb44aa00e8e11"297512STANDARD17/spleen.pdf2018-08-10T15:07:21.000Z"b61dcec8bf8db55111bb799b90e4781e"81939STANDARD17/suspectedbacterialmeningitisormeningococcalsepticaemiainimmunocompetantadultsmarch2018.pdf2019-02-06T15:53:48.000Z"4d5618449468b4ccabe8af50b0900c27"66681STANDARD17/suspectedbacterialmeningitisormeningococcalsepticaemiainimmunocompetantadultsuhlguideline.pdf2018-08-10T15:11:01.000Z"6ac5753017ca0fceb761b6d1915c9d13"33581STANDARD17/treatmentandprophylaxisofinfluenzainadultsb332018.pdf2019-02-12T11:01:20.000Z"6f7592ab2a04db28de0d5dac4a198f4b"159331STANDARD17/typhoidandparatyphoidentericfeverinadultstreatmentguidelinesjan2019.pdf2019-02-05T16:37:02.000Z"a68da245c8f58ca2af5bf3f9e627613f"79852STANDARD17/typhoiduhlchildrensmedicalguideline.pdf2019-03-05T12:05:47.000Z"fc3b2dd88a26df63f7178bb34a296ff7"141681STANDARD17/uhlchildrensgentamicinprescriptionmar2013.pdf2016-12-28T11:51:02.000Z"19de787235c5ed5702eb9559a1de8808"61433STANDARD17/uhlchildrensneonategentamicinprescriptionnov2010.pdf2016-12-28T11:56:59.000Z"f38993befa997ba62eaf8c7a2a6a5fde"58079STANDARD17/utiurinarytractinfectionuhlpaediatricemergencydepartmentguideline.pdf2017-07-14T10:34:57.000Z"1f02f6f96a87430463b79895ce043b82"959387STANDARD17/vaginaldischargeinprepubertalgirlsuhlchildrensmedicalguideline.pdf2018-11-19T11:33:26.000Z"5ce33d080ff8763496e29ae81f74ec09"71018STANDARD17/valproateandcarbapenemsinteractionmanagementuhlguideline.pdf2018-11-20T11:01:57.000Z"8d8f55e26cb0afc0cc90abef8c9e9e27"316541STANDARD17/vancomycinchartforusewithdoseme.pdf2018-08-17T15:00:58.000Z"05a669c60cf89099b22e5ba3699fd678"564232STANDARD17/vasculitiswithrenalinvolvementuhlrenalguideline.pdf2018-11-20T09:43:13.000Z"f1fc6b7afa70716557af8c171152007d"131603STANDARD17/vzvchickenpoxinchildren.pdf2017-05-15T14:22:59.000Z"f2d241c6b2b85c11e7780da27081cc73"449560STANDARD17/womensantimicrobialguidelinessummary.pdf2018-01-30T10:01:56.000Z"f58e8887edbb0c6ec2244532eb373707"78144STANDARD18/ASSESSMENTOFPENICILLINALLERGY.docx2016-11-27T12:59:34.000Z"f2db6bdf6682fb54458004f7ff4117e7"16060STANDARD18/AmikacinDosing.docx2016-11-27T12:59:34.000Z"e0bbd873369f31beba1a70c4fa044f7e"15704STANDARD18/buiantibioticpolicyflowcharthighriskpts.docx2018-07-27T13:54:23.000Z"e8026fc93dfec9ecc76af3c720d8e0c5"103161STANDARD18/gentamicindosing.docx2017-06-07T12:38:39.000Z"445575f572cd2de98e1d33771bc4c12d"18122STANDARD19/AntimicrobialPrescribingPolicy2015.pdf2016-11-27T12:59:35.000Z"e130c7554c5d3e304ddf6a9c72b6db2c"374554STANDARD19/EarlyManagementofSuspectedBacterialMeningitisandMeningococcalSepticaemiainImmunocompetentAdults.pdf2016-11-27T12:59:35.000Z"3c71fe6ca8db832e17053b11947d3cc2"181889STANDARD19/HinchingbrookeTransparentsml.png2016-11-27T12:59:36.000Z"1b1c6e070e22f0f1af646a7a6fe1ac06"20686STANDARD19/PenicillinAllergyPoster.pdf2016-11-27T12:59:36.000Z"c59dfbf0cb73ec8d1798eb30d6d017dd"206072STANDARD19/ProcedureOPAT2014vs2.0.docx2016-11-27T12:59:36.000Z"9151ecf07e448bbdb845d73f7d1a0b84"34312STANDARD19/ProcedureOPAT2015v3.0.docx2016-11-27T12:59:36.000Z"201125cfb3d5486e8c99840e52447a29"33836STANDARD19/RectalVancomycinProtocol2015.docx2016-11-27T12:59:36.000Z"47ea2486e6a759045d216c80d5447a5e"32412STANDARD19/VancomycinInjectionforOralUse.doc2016-11-27T12:59:36.000Z"9e1e668e7760b82cfbe4f0d6247827dc"1445888STANDARD19/VancomycinIntracolonicEnemaProtocol2015.doc2016-11-27T12:59:37.000Z"12ebc4c28177d0cba2f0765bbb8ae7a1"52224STANDARD19/interimantibioicguidelinesduringthenationalshortageofpiperacillintazobactam.pdf2017-05-30T17:46:46.000Z"7a2a359c378c9b748868387d5791313a"222752STANDARD21/gentamicin.pdf2018-03-21T15:41:45.000Z"63a4fc3b21403cd46aa6bf1452df1502"412441STANDARD21/teicoplanin.pdf2018-03-21T15:41:38.000Z"3e0faaa555dcf926e9ae533099402a6c"447629STANDARD21/vancomycin.pdf2018-03-21T15:41:29.000Z"868dc12148f7155f1a367e95673e1d08"554006STANDARD23/1.ibwcrclcalculator1.4.16.docx2016-12-05T09:32:01.000Z"e107cd4ab5c1b434cdea1e3299d66c38"15514STANDARD23/201603161307360.antibioticguidelinesforobstetricsandgynaecologyv3.0.pdf2016-12-14T10:55:33.000Z"99f889b44900494b06327b7685155cfc"309488STANDARD23/oralabx.png2016-11-27T12:59:42.000Z"3aa50bfde83106e834472fabd212219b"198607STANDARD23/reorder.png2016-11-27T12:59:42.000Z"7b48365d8307c0b36b1fe62ebf1a65d0"82696STANDARD23/uploadimage.PNG2016-11-27T12:59:42.000Z"5723122e6490ae9f72bb13f1d3bda579"71607STANDARD24/Biogram1.jpg2016-11-27T12:59:43.000Z"d40a24bdf6961a094be9dce16fc7dff8"237437STANDARD24/Biogram2.jpg2016-11-27T12:59:44.000Z"ccb7e12a23e65207c28e0c9249a52733"232115STANDARD24/StartSMartMedicine.jpg2016-11-27T12:59:46.000Z"6fa2128a700d5c60ce99896c23c2c9c6"159701STANDARD24/StartSMartSurgery.jpg2016-11-27T12:59:46.000Z"662b9a65461b9937207e957dc61f8dbf"115676STANDARD24/akiaciclovir.jpg2017-05-08T07:56:39.000Z"5b4ed38cbe0cdb8200795ce5be759c1f"112722STANDARD24/akialertapp.jpg2017-05-08T07:50:36.000Z"631a8a4312f286341783d79dd89800b5"94535STANDARD24/akiamikacin.jpg2017-05-08T07:57:19.000Z"3700ed0d8d4a0ba48097e93f779b2f42"134215STANDARD24/akiantif1.jpg2017-05-08T07:58:42.000Z"544a333492fbb01a4d730f9e385646bb"144326STANDARD24/akiantif2.jpg2017-05-08T07:58:57.000Z"e6af474193c1e19ae263b64dbead2c31"61979STANDARD24/akitb.jpg2017-05-08T08:35:56.000Z"bdaef8501cb90df5f5e671d367e91e1b"138737STANDARD24/ambopos.jpg2018-09-19T07:49:19.000Z"c027b3f24c67df9021e956cd1c8a0875"137046STANDARD24/amoxceph.jpg2018-09-19T07:39:08.000Z"0dacab685405c727df480e9d52f49662"134046STANDARD24/cephtcip.jpg2018-09-19T07:40:08.000Z"b1de525ab750fbdbc14e5c88a69a0c6f"148056STANDARD24/claidaps.jpg2018-09-19T07:40:35.000Z"6154f8cd0060dae3851bbab446af0781"131931STANDARD24/daptfluclox.jpg2018-09-19T07:41:37.000Z"ea7cd18db629f0efe8b78010c7c1cf52"118983STANDARD24/dosinginakiapp.jpg2017-05-08T07:51:08.000Z"98f9f4dd9fda2c7f3eacd26dd460e11f"86415STANDARD24/fosmetro.jpg2018-09-19T07:41:42.000Z"3c60c04c4025e818999f876bc6e1d71b"142463STANDARD24/nitroteci.jpg2018-09-19T07:42:10.000Z"e503d9a743cf483b2a67eb9fd9893894"118540STANDARD24/penallergytrafficlight.jpg2018-09-19T07:53:31.000Z"7391b373026b367dc4ef86b692577e97"144702STANDARD24/terbvori.jpg2018-09-19T07:50:24.000Z"415845b8c72e478cb0aab2650a07c01e"71067STANDARD24/tetrvanc.jpg2018-09-19T07:42:33.000Z"abc3ad9459658368cbfe446e9b2c5a3f"118134STANDARD3/BSACMaintenanceDec2013.pdf2016-11-27T12:59:51.000Z"9fe7afee2cf5e46fecf8e90445694c3d"73164STANDARD3/DeclarationofConsentAACP.pdf2016-11-27T12:59:51.000Z"2cf843894e52dec920846e083bf4d30a"196574STANDARD3/IMG6047.png2016-11-27T12:59:51.000Z"1d1924e7c444fbda6a9fe2c3be7aab09"34444STANDARD3/PreviewOne.png2016-11-27T12:59:51.000Z"1c2db43e4b656d2fed6eef3e6d4f8062"12568STANDARD3/RxBanner.png2016-11-27T12:59:51.000Z"591aece2e80ebb7f4c5bc1424fa46750"16805STANDARD32/SouthTynsideimage.png2016-11-27T12:59:52.000Z"75055500344dab66d8263dc7f6e2980f"40512STANDARD32/antimicrobialimprovementsstfposterfinalversionpdf.pdf2017-07-28T15:28:08.000Z"db916d8d6e2a84a3c48331291e8692d3"452656STANDARD32/capturesstf.jpg2017-03-23T14:38:40.000Z"2d05b6c0077112a7770f54a644e0e165"16809STANDARD32/choose4png.PNG2016-11-27T12:59:52.000Z"2616e59b1f060a19639475ea37ffe623"47146STANDARD32/choose6.PNG2016-11-27T12:59:52.000Z"5d7ae7f6c0a4628f0ab76712dae65885"17289STANDARD32/logo.png2017-09-19T21:00:23.000Z"2b70a36d6023864acdecac2948d2aefa"12168STANDARD32/managementoforalcandidiasisinteractionsinformationjan17.pdf2017-02-08T15:54:53.000Z"54a9ba454935f5c69e6d7aa5f8f8fbaf"161758STANDARD32/microresctricedtrafficlights.jpg2019-04-26T14:39:01.000Z"e9ca9dc4fcc213de55f39ff8152086d7"112404STANDARD32/neandcantimicrobialprescribingguidelinev2.2final1.pdf2017-07-28T15:11:25.000Z"e0cabda0520bb669113da7d15a6f5ab1"995792STANDARD32/necantimicrobialprescribingguidelinev4.11.pdf2018-08-30T11:33:04.000Z"88b02f2ab238e3e0a24336551819b354"1184872STANDARD32/penicillinallergyposterpdfversion.pdf2019-03-15T14:30:28.000Z"7f491d3c899ad3a30082353b16f9ba53"475335STANDARD32/pheutiflowchartchildren.pdf2018-12-11T08:15:23.000Z"dfab56373dcb1bd673af642c672f0a28"122871STANDARD32/pheutiflowchartover65.pdf2018-12-11T08:15:03.000Z"3ddeaecb3b02513357e38c03dcfdd4e9"294073STANDARD32/pheutiflowchartunder65women.pdf2018-12-11T08:15:17.000Z"a5cdb08b933b2efd80647e1ca164d248"234115STANDARD32/southtynesideandsunderlandnhsft.jpg2019-04-26T14:40:06.000Z"6f3b5695eb80946dcba88a7f34021ae7"183311STANDARD35/hospitallogo.png2016-11-27T12:59:53.000Z"80ad6315aea547f44d7453b5188bbf8f"17668STANDARD35/nhslogo.png2019-05-14T17:49:30.000Z"53d9c1f156000fcdf06a2217dbb324be"35290STANDARD35/teamstructure.png2019-05-13T14:53:17.000Z"b5c6f09ea54858aa628af9fccacd8011"16359STANDARD40/APPENDIX2TreatmentProtocolforOnceDailyGentamicininAdults.docx2016-11-27T12:59:55.000Z"42828c42445642abb6e1aae925c628b0"24791STANDARD40/AbxCDIRisk.png2016-11-27T12:59:55.000Z"3ea823fb8b710eb8aae87480ae20ea47"20517STANDARD40/AcuteupperGIbleeding.doc2016-11-27T12:59:55.000Z"88fd38fe65a855059901f3f8383e4a17"496128STANDARD40/CDIAlgorithm1.png2016-11-27T12:59:56.000Z"728bf6bdde2880466d5683e4a4b995f6"77576STANDARD40/CDIAlgorithm1title.png2016-11-27T12:59:56.000Z"99ed9a9e42a7f234f9672d8aeb387511"3217STANDARD40/CDIAlgorithm2.png2016-11-27T12:59:56.000Z"113772e29b36dd91fb77c92c7a6f3eb6"51234STANDARD40/CDIAlgorithm2Title.png2016-11-27T12:59:56.000Z"64330973a755d1a3213fe4b8ec744614"5961STANDARD40/CDISeverityAssessmentPaeds.png2016-11-27T12:59:56.000Z"e58c05a2ddddfaeabc3b3e74cf2bdaec"37048STANDARD40/CDITreatmentRecommendations.png2016-11-27T12:59:56.000Z"7aa9adb888422f0fc5dba4d6eaa01b59"42279STANDARD40/CDITreatmentRecommendationsPaeds.png2016-11-27T12:59:56.000Z"2e8e1de057db27de7b84f0e486182df8"40360STANDARD40/CapSEVERITYASSESSMENT.png2016-11-27T12:59:56.000Z"729a1b4519c1ad34c02cebefa9e9e679"20443STANDARD40/ChrohnsDiseaseGuideline.doc2016-11-27T12:59:57.000Z"40bd8c608451e686fa842831c6160749"424960STANDARD40/EndocarditisFlowChart.png2016-11-27T12:59:57.000Z"1375fef72aa009ff835298fa94df4691"1117785STANDARD40/EndocarditisRecommendations.png2016-11-27T12:59:58.000Z"055c749aa9f2d4ba9a89a736a77134ed"106201STANDARD40/GentamicinDosing.png2016-11-27T12:59:58.000Z"de5b5d8b8c1320584fa4e13e30a1113a"7326STANDARD40/GentamicinLevels.png2016-11-27T12:59:58.000Z"83edb9bd8270fa74061819f0aeb0eeca"12334STANDARD40/Gentamicindosinginobesepatients.png2016-11-27T12:59:58.000Z"91261a744d6692e5eb82a6d4e1b6ccab"14261STANDARD40/InitialManagementGuidelinesforSuspectedMeningitisinAdults.docx2016-11-27T12:59:58.000Z"681fb8c7eb8a972a29663d0e4f611460"120805STANDARD40/MRSATreatmentTable.png2016-11-27T12:59:59.000Z"3e4d7a15ee0afca025afe98d7625dc7d"35000STANDARD40/MRSATreatmentrecommendations.png2016-11-27T12:59:59.000Z"1456095fa31e48ba367cf6a6649d4192"34976STANDARD40/MalignantandNonMalignantAscitesManagment.doc2016-11-27T12:59:58.000Z"7cad381d73298658a30a5f606ad1998d"399360STANDARD40/Neutropenicsepsis.doc2016-11-27T12:59:59.000Z"1924082842fe95e3bf60d0dff662cf44"428032STANDARD40/PenicillinAllergydrugs.png2016-11-27T12:59:59.000Z"9ffcb0b9041ced0d53d35feacab3ff5c"35656STANDARD40/Picture2.png2016-11-27T13:00:00.000Z"5c6afa81d032e683d6509e1bae2eec84"3990STANDARD40/Picture3.png2016-11-27T13:00:00.000Z"00db4521f55b9ec6cb0f570a7a92fa54"5647STANDARD40/Picture5.png2016-11-27T13:00:00.000Z"997be28d55122b4efa11d405508c2729"61570STANDARD40/SSTF.png2016-11-27T13:00:01.000Z"105b0ceeea805ec9dc9a634a8567e316"280006STANDARD40/SepsisAlgorithm1.2.png2016-11-27T13:00:00.000Z"c153fe2f3d3ab9ae16771baba4372c8d"31947STANDARD40/SepsisAlgorithm1.3.png2016-11-27T13:00:00.000Z"6c2a68bc98a377bd5b9e1ff6fb529b0a"32751STANDARD40/SepsisAlgorithm1.png2016-11-27T13:00:00.000Z"009a79ccc435175a5745b9c3f5664c9f"33660STANDARD40/SepsisFirstStagerevised24212.doc2016-11-27T13:00:00.000Z"2a411f4fd9be76424c08366b51fd14d0"446464STANDARD40/SepsisSix.png2016-11-27T13:00:00.000Z"1dfc27691b2938a53f2968285cd94067"40839STANDARD40/TeiccoplaninCrClDose.png2016-11-27T13:00:01.000Z"ba3a21b765d2e165a06cddc7ead340df"9006STANDARD40/TeicoplaninMonitoring.png2016-11-27T13:00:02.000Z"f0055087d4424566b839275cc0392164"6444STANDARD40/VRE.doc2016-11-27T13:00:03.000Z"3322373f0fe617d43a7ca3d9b72c3296"79360STANDARD40/Vancomycin.png2016-11-27T13:00:03.000Z"d61cca4d357d42d62f8e646f821fe6e2"73433STANDARD40/Vancomycin2.png2016-11-27T13:00:02.000Z"4a1e4d587802d441dd98ff40aa92f29d"80505STANDARD40/Vancomycin3.png2016-11-27T13:00:02.000Z"30c40f8d06b093fdc987e4f982ddc3a8"81429STANDARD40/acutecolitisguideline.doc2016-11-27T12:59:55.000Z"9fbbda0482eb1e2aac68121b17476409"421376STANDARD40/ddlfluroquinolonesmarch2019final.pdf2019-03-29T13:00:38.000Z"0a7775626dc8cabe3ad6af223101e610"105370STANDARD40/severepenicillinAllergy.png2016-11-27T13:00:01.000Z"1c7425ede6b1a49fd19c64540230bb0f"16235STANDARD40/surgicalprophylaxisalgorithm.png2018-08-16T11:48:07.000Z"5b9c92bf33d46d2ffb14163106607c2a"373611STANDARD44/WalesDeanerypng330x225.png2016-11-27T13:00:13.000Z"59239a62f331a076e121157a392da37b"39152STANDARD44/hba1c.png2017-01-02T23:01:25.000Z"95c705ff67f265a01016a268ab4edd4d"150563STANDARD44/lipidsnice.png2017-03-31T10:29:08.000Z"854df55feda915b7f296539be0ef0411"45066STANDARD45/AACPathway.jpg2016-11-27T13:00:13.000Z"cf210d469f3b722de507a9db3c1a3b89"2578092STANDARD45/AACPathway1.jpg2016-11-27T13:00:15.000Z"cf210d469f3b722de507a9db3c1a3b89"2578092STANDARD45/CiviLetter7.pdf2016-11-27T13:00:16.000Z"50f620e789ead278f6e18a2c8da1209a"3586STANDARD45/MNDAssociationlogo.png2016-11-27T13:00:16.000Z"c3ff45cd71c39ca601a3cb2eb7a5832c"289521STANDARD45/MNDRespiratoryPathway.jpg2016-11-27T13:00:17.000Z"452edf6e7458209a082df4a613621e2e"3369951STANDARD45/MNDRespiratoryPathwayv1.1070615.jpg2016-11-27T13:00:16.000Z"0515621c59ef24668250f2f99d0ab129"1255960STANDARD45/RedFlagtool.jpg2016-11-27T13:00:20.000Z"529270c0b2c2c23c5de953c15cf7071c"2551467STANDARD45/RedFlagtoolpage2.jpg2016-11-27T13:00:19.000Z"b5512daaf3a53d3e9c6602e588764070"2854498STANDARD45/Rxguidelineslogo.png2016-11-27T13:00:21.000Z"3105db3713ce20e0ff4c9b843719a2c7"70921STANDARD49/ark.jpg2018-11-05T10:12:49.000Z"8931bc4941694dd6007687f5354fe061"5951STANDARD49/ark1.1.png2018-11-01T11:04:43.000Z"6691b8e03207bd64dfb1d6d073c874dd"86101STANDARD49/arkpossible1.png2018-11-01T11:04:57.000Z"230954c06e87814e1c144325e7e495c4"45180STANDARD49/arkpossible2.png2018-11-01T11:05:08.000Z"887782fa2d6a1a4f51b3d05a324feac3"52016STANDARD49/arkprobable1.png2018-11-01T11:05:20.000Z"fb0a4408b14bfdd8d035dd6de12ec5cd"50057STANDARD49/arkprobable2.png2018-11-01T11:05:32.000Z"23b94c13b798e5718e5a8e1e7bec5519"65595STANDARD49/c.difftx2018.jpg2018-11-01T10:36:27.000Z"927450d115634cdf4763be13999f57a1"320875STANDARD49/dfi2018.png2018-11-06T13:42:03.000Z"0b78dbb5e3d12d260ca035ec073915cf"469271STANDARD49/doc1.jpg2016-11-27T13:00:23.000Z"ea6da79f45007415d049938254bf97fa"157763STANDARD49/doc3.jpg2016-11-27T13:00:23.000Z"82b8584d4c0979d8c8e01102c899e63c"171040STANDARD49/doc4.jpg2016-11-27T13:00:24.000Z"5a9a3336c60c8d50aa4804e74cd7b64a"167470STANDARD49/doc5.jpg2016-11-27T13:00:24.000Z"5a9a3336c60c8d50aa4804e74cd7b64a"167470STANDARD49/doc6.jpg2016-11-27T13:00:24.000Z"36174927d5dbfd567d2ed007f790697d"130621STANDARD49/noeflowchart.png2018-11-12T10:49:19.000Z"3b0c0146228b74d8923b4c25d822e03e"129846STANDARD49/pic1.jpg2016-11-27T13:00:24.000Z"875fb8b7a63d6d908e858bab99dedd35"90973STANDARD49/vascularflowchart.png2018-11-06T13:47:46.000Z"46ef5aab49d5bb715c927b146bf7722e"44214STANDARD5/2015GRCDPM0101PaediatricEmpiricalAntimicrobialCardWeb.pdf2016-11-27T13:00:25.000Z"3277e5049a98a8be12e03e1963baa0c2"230859STANDARD5/AntibioticPrescribingGuidelinesPaedRDEaug2015.doc2016-11-27T13:00:26.000Z"40e4457e771300dce332fd93832bfd5c"174080STANDARD5/AntibioticPrescribingGuidelinesPaedRDEaug2015.pdf2016-11-27T13:00:26.000Z"d5fa3659496a41898a2e28736bd069ed"180481STANDARD5/Antifungal20prophylaxis.pdf2016-11-27T13:00:26.000Z"d948faba56de518c1dda90d462af2fcf"45697STANDARD5/Antifungalprophylaxis.pdf2016-11-27T13:00:26.000Z"d948faba56de518c1dda90d462af2fcf"45697STANDARD5/AntimicrobialsListOCT12V7.pdf2016-11-27T13:00:27.000Z"503989b78068609d1490b05f79b8f624"513748STANDARD5/Aspleniavaccinesandprophylaxis050515.pdf2016-11-27T13:00:27.000Z"9baa1ec68e23bf9c999898a1b59c8be6"416296STANDARD5/CAP171114chloramremoved.pdf2016-11-27T13:00:28.000Z"719116be75dea19ed2e24e3a67c06201"174894STANDARD5/CAPv9150515.pdf2016-11-27T13:00:28.000Z"b15e25a98e12478335fcc3a0d9830d4b"490362STANDARD5/CAPv915update16.docx2016-11-27T13:00:29.000Z"d803a55a42002701033cec6f5afa0c85"68235STANDARD5/CDIalgorithm.png2016-11-27T13:00:29.000Z"aca196438c39d21be56df6a27689fb7f"1123742STANDARD5/CDIalgorithmV2.png2016-11-27T13:00:29.000Z"aca196438c39d21be56df6a27689fb7f"1123742STANDARD5/Capture.PNG2016-11-27T13:00:28.000Z"0adabd57630d551c2392cf2e93e6bb86"77137STANDARD5/CaptureII.PNG2016-11-27T13:00:28.000Z"0adabd57630d551c2392cf2e93e6bb86"77137STANDARD5/Diabeticosteomyelitispathway160315.pdf2016-11-27T13:00:30.000Z"020371871ca844e47e2621d36b4e2095"425593STANDARD5/Diabeticskinandsofttissueinfections160315.docx2016-11-27T13:00:30.000Z"399612c50c96648a930822e1eade9fef"95870STANDARD5/Diabeticskinandsofttissueinfections160315.pdf2016-11-27T13:00:30.000Z"b3f29e0f6732d4b60520e51c873e34ac"418923STANDARD5/DiabeticskinandsofttissueinfectionsSept12Verison3forapp.pdf2016-11-27T13:00:31.000Z"e23be261bbe324b13ca3c5638ba97c93"158746STANDARD5/DiabeticskinandsofttissueinfectionsSept12Verison4notaz.docx2016-11-27T13:00:31.000Z"4ac3e50719deface0189d32fecf851db"60924STANDARD5/DipstickAlgorithm21716.doc2016-11-27T13:00:31.000Z"25799493ff753e85757837ae24167996"39936STANDARD5/DoH2014to2015guidanceverison5antiviral.pdf2016-11-27T13:00:31.000Z"6f7a659edc7cc5205693fea370e480c9"248647STANDARD5/Empiricalsurgicaltreatmentguidelinescotrimoxandchloramremoved171114.pdf2016-11-27T13:00:31.000Z"cad265623d2506467b07aa0adf84d553"199907STANDARD5/Epididymoorchitissept12fromIaN.pdf2016-11-27T13:00:32.000Z"5e03de0752c80c6934ec0a5454dc02dc"101876STANDARD5/Fluflowchart201516update121115.JPG2016-11-27T13:00:32.000Z"00b8919f9ccef14d4175dbe91c66df1a"171705STANDARD5/Fluflowchart201516update161015.JPG2016-11-27T13:00:32.000Z"646dc0667bf9e32af05e2640331da0e1"170797STANDARD5/FosfomycinPIL.pdf2016-11-27T13:00:32.000Z"2c861d02110abb9fe0d8abc61806a514"26013STANDARD5/FosfomycinProforma2010.pdf2016-11-27T13:00:32.000Z"b05045f94c31d0b07692b59d8534a643"46876STANDARD5/FosfomycinSPCfrenchtranslation.pdf2016-11-27T13:00:33.000Z"6d0c60112b49cd969a3027bba08c3dba"74642STANDARD5/GRCDPM0102PaediatricEmpiricalAntimicrobialCardWebupdatedNov2015FINALVERSION.pdf2016-11-27T13:00:33.000Z"5db6435137a33ca28964809b8abac345"236406STANDARD5/GRPTPM0102OrthopaedicprophylaxisguidelinesWEBDec15.pdf2016-11-27T13:00:33.000Z"f586fc87a266e084b49de495a32f3abf"218295STANDARD5/GRPTPM0202ObsandgynaeprophylaxisguidelinesWEBJan16.pdf2016-11-27T13:00:34.000Z"1dcf5edf73164ba0a783848eb7bdd6bd"181684STANDARD5/GRPTPM03012020Surgical20prophylaxis20guidelines.pdf2016-11-27T13:00:37.000Z"e71e70baa2e632b75bffb5d71b073c3e"154842STANDARD5/GRPTPM0301Surgicalprophylaxisguidelines.pdf2016-11-27T13:00:35.000Z"e71e70baa2e632b75bffb5d71b073c3e"154842STANDARD5/GRPTPM0302Surgicalprophylaxisguidelinesweb.pdf2016-11-27T13:00:38.000Z"5200bb3979db3523db160474903615e6"200220STANDARD5/Generalandspecialistsurgeryprophylaxisguidelines.pdf2016-11-27T13:00:33.000Z"efdcd72057872764fbead347b1f10489"153148STANDARD5/GentextendedintervalIVforadultsJuly2013V1.pdf2016-11-27T13:00:33.000Z"0d61a9548c25d763275d610aab50f08d"425428STANDARD5/HAP171114chloramremoved.pdf2016-11-27T13:00:38.000Z"9e8aac24ba8d698968296b4135ccae18"145536STANDARD5/HAPv9150515.pdf2016-11-27T13:00:38.000Z"d6f5d5522369968ab88e5d5fb14e8380"558124STANDARD5/HAPv915update16.docx2016-11-27T13:00:39.000Z"e4a8cc34041b1f03ff61f72467ad8584"57091STANDARD5/ITUAdulttreatmentguidelinesV4181116notaz.docx2016-11-27T13:00:39.000Z"a90cc7b5d667573ac5c1e88a52f54cb9"68251STANDARD5/ITUv3.pdf2016-11-27T13:00:39.000Z"71930fb2de1deade34898bce253e36b0"541624STANDARD